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PREFACE

Pharmaceutical companies first marketed prostaglandins in the 1970s. Misoprostol (Cytotec®), an
orally active prostaglandin E1 analog, was
approved in 1988 by the U.S. Food and Drug
Administration for use in preventing gastric ulcers
associated with use of nonsteroidal antiinflammatory drugs. For over a decade, however,
researchers and clinicians have explored the use
of this compound for a range of women’s health
indications. The literature on the subject is substantial, and anecdotal reports suggest that misoprostol is currently used for many indications.
Such use has become common for several
reasons, including a need for better, simpler, and
more cost-effective alternatives to standard treatments for incomplete abortion and labor induction. Moreover, development of nonsurgical interventions has high value, because such less-invasive interventions are often safer, preferable to
patients, easier to deliver, and able to be provided
by a range of health care practitioners. Use of misoprostol has also been motivated by the need to
provide better health care for women in resourcepoor environments and to increase women’s autonomy in health care decisionmaking everywhere.
The impetus for the meeting summarized in
this report was the recognition that the large body
of high-quality scientific work on misoprostol for
women’s health indications has not been synthesized in an accessible way. Scientists working to
develop the potential of misoprostol have generally done so with very little collaboration or support
from pharmaceutical companies or governmental
research institutions. As a result, there has been no

Beverly Winikoff, M.D.,
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President
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consensus on issues surrounding the use of misoprostol for women’s health and no strategic agenda
for continuing development, with most research
proceeding in an ad hoc manner. Undeniably, impressive progress has been made in developing
misoprostol for women’s health indications despite
unpromising circumstances. We realized, however,
that there was much to be gained by coming together in order to summarize the current state of the
field and to collaborate in planning for the future.
We have many hopes for misoprostol. We
anticipate that a solid clinical base for use of misoprostol for women’s health indications can be
developed along with greater awareness of the
science and importance of this drug. To this end,
we hope to see more widespread, accurate, and
appropriate dissemination of information on misoprostol, and misinformation dispelled. Finally, and
perhaps most important, we look forward to seeing
a dedicated product for women’s health indications
on the market. In many regards, this meeting was
a call to action. The 58 participants—researchers,
providers, women’s health advocates, and educators—unanimously acknowledged misoprostol’s
promise to improve women’s health. We hope
that this report will motivate new strategic and
collaborative efforts in research, advocacy, education, and regulatory matters to protect and to support this promise.
Note: This meeting was convened in May 2001.
Given that many articles on the use of misoprostol
for women’s health have been published since, we
have taken the liberty of updating the bibliography
to include these recent publications.

Felicia H. Stewart, M.D.

Caitlin Shannon, M.P.H.

Co-director
Center for Reproductive Health
Research & Policy
University of California,
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Program Coordinator
Population Council
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INTRODUCTION

On 7 and 8 May 2001, the Population Council and
the Center for Reproductive Health Research &
Policy of the University of California, San Francisco,
convened a technical seminar in New York City on
the use of misoprostol for women’s health indications. The seminar was designed to provide a
forum for researchers, providers, women’s health
advocates, and educators to exchange information
with the goal of advancing the potential of misoprostol to improve women’s health. In presentations and question-and-answer sessions, participants discussed the state of the art in research,
examined current clinical use of misoprostol, and
created strategies for the future.
The three main objectives of the seminar were to:
• share research and clinical experience;
• identify promising regimens for use of misoprostol in women’s health; and
• target priorities and potential strategies
for research, education, policy, and
information dissemination.
The first day focused on scientific and clinical
aspects of misoprostol use. Leading experts discussed the current research for each indication,
including dose, route of administration, regimens,
efficacy, and side effects. Unpublished research (completed or in progress) also was discussed to ensure
the most current understanding of the science.

1

The second day’s discussion centered on the
future of misoprostol for women’s health, including identifying priorities for research and the role
of provider groups and women’s health and advocacy organizations in helping to ensure misoprostol’s continued, appropriate use.
At the end of each session, discussion provided the group with an opportunity to share ideas
and discuss unanswered questions.
This report covers the key issues raised by
each speaker and highlights general areas of discussion among participants. Three main sections
follow:
• a summary of available clinical research,
which describes current research on each
indication for which the use of misoprostol
has been investigated, highlighting gaps in
research and issues relevant for the transfer
of the technology from research to practice;
• a summary of current medical practice,
reviewing results of studies that investigated the use of misoprostol in women’s
health care, including providers’ and
women’s knowledge of misoprostol and
regimens and the indications most commonly used; and
• a list of priorities for research and policy.
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BACKGROUND

Misoprostol’s Importance for
Women’s Health
Misoprostol is currently marketed by Pfizer Inc.*
as Cytotec® for the prevention of gastric ulcers
induced by the use of nonsteroidal antiinflammatory drugs (NSAIDs). Cytotec® is registered for use
in over 80 countries (see Figure 1). Several generic
misoprostol products have recently become available for this indication.
A review of the literature reveals that research
on misoprostol for women’s health indications has
been expanding rapidly since the beginning of the
1990s. The extensive body of published literature
demonstrates misoprostol’s potential for a range
of women’s health indications (see Box 1). These
indications can be broadly categorized into one of
three areas: abortion, uterine evacuation, and
labor and delivery (see Box 2).

Advantages of Misoprostol
Misoprostol is inexpensive, easy to store, and
widely available. Alternatives to misoprostol for
certain indications include prostaglandins such as
gemeprost and dinoprostone (Prostin®, Prepidil®,
and Cervidil®) and uterotonics such as oxytocin or
Syntometrine® (oxytocin and ergometrine). These
alternatives are more expensive, require refrigerated storage, and often are given by injection.
Compared to these other products, misoprostol
has the potential for widespread use, particularly
in low-resource settings where the burden of
reproductive mortality and morbidity is heaviest.
Moreover, treatment with misoprostol is noninvasive, simple to provide, and may be preferable to
women. It can be provided in a range of settings,
including hospitals, family planning clinics,
mobile units, and at home (see Boxes 3 and 4).

* From 1988 until 2000, Cytotec® (misoprostol) was marketed and distributed by G.D. Searle & Company. Monsanto Company,
including its G.D. Searle unit, merged with Pharmacia & Upjohn in April 2000, creating Pharmacia Corporation. On 15 July 2002,
Pharmacia Corporation and Pfizer Inc. announced that Pfizer would acquire Pharmacia. This merger was completed on 16 April 2003.

FIGURE 1

Availability of misoprostol worldwide, July 2003

Misoprostol available
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BOX 1

State of current research on misoprostol

Indications for which there is an extensive, well-established body of
evidence

• First- and second-trimester pregnancy termination in conjunction
with mifepristone or methotrexate
• Cervical ripening before first-trimester surgical pregnancy
termination
• Labor induction with a viable fetus
Indications for which there is good evidence, including at least one
published randomized, controlled trial, and that were discussed at
the meeting

• First- and second-trimester pregnancy termination with
misoprostol alone
• Management of miscarriage and incomplete abortion
• Labor induction for intrauterine fetal death
• Prevention and treatment of postpartum hemorrhage
• Cervical ripening before hysteroscopy and other gynecological
procedures that require entry into the uterus
Indications for which there is anecdotal evidence or potential use
but few published studies, and that were not discussed at the
meeting

• Cervical ripening before second- and third-trimester dilation and
evacuation
• IUD insertion or endometrial biopsy
• Enhancement of pregnancy rates with intrauterine insemination

BOX 2

Women’s health indications for misoprostol

Abortion
Misoprostol is an effective abortifacient when used alone or in conjunction with other drugs such as mifepristone or methotrexate. It can
be used to induce abortion at any point in gestation. At later gestational ages, misoprostol can be used either to induce labor or as part
of a dilation and evacuation procedure. The drug is also used for cervical ripening prior to first-trimester aspiration abortion.
Uterine evacuation
Misoprostol may be instrumental in treating women who experience
pregnancy failure requiring evacuation of the contents of the uterus.
Labor and delivery
Some providers use misoprostol to prime the cervix and augment
other labor-inducing drugs such as oxytocin, while other providers use
misoprostol alone to induce labor. Some studies have also suggested
that misoprostol may prevent and treat postpartum hemorrhage.

Obstacles to the Use of Misoprostol
Despite misoprostol’s promise, obstacles limit its
widespread and appropriate use. There is reluctance within some health care delivery systems to
make this compound widely available. Further,
political controversy sometimes blocks access, and
unanswered research questions render it difficult
to develop clear guidelines for use. One of the
most important obstacles, however, is that no
commercial entity has registered misoprostol for
its women’s health indications, partly because of
the political climate surrounding its abortifacient
properties. As a result, research and development
of misoprostol have proceeded in an ad hoc manner, with no formal development plan for its registration and introduction.
BOX 3

Prostaglandins: A primer

What are prostaglandins, and how do they work?
Prostaglandins are lipids made up of modified fatty acids attached to a
five-member ring. There are about 20 naturally occurring compounds in
this class. They act in a manner similar to that of hormones, stimulating
target cells into action. However, they differ from hormones in that they
act locally, near their site of synthesis, and are metabolized very rapidly.
As a result, the same prostaglandins act differently in different tissues.
Naturally occurring prostaglandins are produced by many organs
and tissues and have a wide range of action. For example, they can
cause contractions of smooth muscles, such as in the uterus or intestines; cause dilation of blood vessels; or mediate the inflammatory
response (aspirin and other NSAIDs act by blocking prostaglandin production). Prostaglandins are also involved in the production of mucus in
the stomach, which provides protection against gastric acid.
Synthetic forms (analogs) of prostaglandins are used for a wide range
of indications, including treatment of gastric ulcers; induction of labor and
abortion, and treatment of bleeding after childbirth; and treatment of
erectile dysfunction, congenital heart disease in babies, and glaucoma.
Commercially available prostaglandins with evidence-based uses
for women’s health indications
E1 analogs
• Misoprostol (Cytotec®, Pfizer)
• Gemeprost (not commercially available in the United States)
• Sulprostone (no longer commercially available)
E2 analogs
• Dinoprostone (Prostin E2®, Pfizer) (preparations include Prepidil®
[cervical gel], Propess-RS® [pessaries], and Prostin E2® [oral
tablets, vaginal tablets, solution, and vaginal gel])
F2-alpha analogs
• Dinoprost (Prostin F2 alpha®, Pfizer) (not commercially available
in the United States)
• Carboprost (Hemabate®, Pfizer)
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BOX 4

Overview of misoprostol

What is misoprostol?

• Synthetic prostaglandin E1 analog
• Approved for prevention and treatment of gastric ulcers secondary to chronic treatment with NSAIDs
• Marketed and distributed worldwide by Pfizer
What properties make misoprostol useful for women’s health
indications?

• Its ability to contract the uterus and ripen the cervix
What are the possible women’s health indications for misoprostol?

• Induction of labor
• Prevention of postpartum hemorrhage
• Cervical priming prior to obstetric and gynecological procedures
• Evacuation of the uterus after pregnancy failure (including treatment of incomplete abortion)
• Induction of abortion in the first, second, and third trimesters
What are the advantages of misoprostol?

Compared to traditional treatments, misoprostol has many advantages, particularly in developing countries.
• Inexpensive
• Stable at room temperature
• Easy to administer
• Multiple modes of administration
• Widely available
What are the key policy and research issues?

• What will happen to the use of misoprostol in the future?
• What will be the role of the pharmaceutical industry?
• How can practitioners and hospital administrators be informed
about its appropriate use?
• How can women’s health organizations facilitate education and
information dissemination?
• What should women know about the potential benefits and dangers of this drug?

Use of Cytotec® (misoprostol) by pregnant
women was contraindicated in the original U.S.
Food and Drug Administration (FDA)–approved
label for the drug. Recently, however, the widespread use of misoprostol for labor induction in
the United States and its inclusion in the FDAapproved label for use with Mifeprex® (mifepristone) for early pregnancy termination were reflected in major changes to the label. These changes
suggest tacit acknowledgment of misoprostol’s various uses for women’s health indications (see Box
5). Although there is an extensive body of highly
technical literature on various off-label uses of
misoprostol, regimens and practice guidelines
have yet to be established for most women’s

health indications. Currently recommendations for
use may come from several informal sources and
may be inconsistent and contradictory, making it
difficult for providers to choose an optimal regimen. Finally, apart from highly technical, scientific
literature, it is difficult to find comprehensive, accurate information on misoprostol’s use in women’s
health. The information that exists also tends to be
contradictory and is not universally accessible.
Nonetheless, use of misoprostol, including selfadministered use, is known to be widespread.
Without proper patient and provider education, the
potential for uninformed use is great, potentially
resulting in poor outcomes and ineffective treatment while negatively affecting efforts to make the
drug widely available and to standardize its use.

Advancing Misoprostol’s Potential
The story of misoprostol is unique: Without any
commercial drug development blueprint or strategy,
and owing in great measure to the creativity and
initiative of a dedicated cadre of physicians, scientists, and researchers, an enormous body of clinical
literature on misoprostol has been created. Neither
special investment nor sanctioned curriculum has
driven this investigation. Indeed, it is rare to have
a technology already at hand that could, with a relatively small amount of investment, reap such a
large return for women’s health around the globe.

Recent changes to the U.S. FDA-approved label
for Cytotec® (misoprostol)
BOX 5

On 17 April 2002 the FDA announced a revision in the drug labeling
of Cytotec®. The changes include the following:
Revision of contraindications regarding and precautions for use in
pregnant women

The label now states that misoprostol is contraindicated only for pregnant women who are using Cytotec® to prevent NSAID-induced ulcers.
Creation of a new labor and delivery section of the labeling, and
provision of safety information related to those uses

Owing to FDA regulations, if a drug has a recognized use in labor
and delivery, drug effect information must be stated, whether or not
the use is stated in the indication section of the labeling.
Addition of new information on misoprostol use and uterine rupture

The label states the uterine rupture following misoprostol use is
known to be associated with risk factors such as advanced gestation,
higher doses of the drug, prior cesarean delivery or uterine surgery,
and having five or more previous pregnancies.
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CURRENT EVIDENCE

IN

CLINICAL

RESEARCH:

U S E O F MISOPROSTOL FOR
WOMEN’S HEALTH INDICATIONS

Induced Abortion with
Misoprostol Alone
Access to safe and effective medical methods of
abortion has the potential to reduce maternal
mortality, especially in low-resource settings
where safe provision of surgical services often is
less feasible. The introduction of mifepristone in
the 1980s was a seminal event in the availability
of medical abortion technology. Use of this drug
in conjunction with misoprostol is highly safe and
effective for termination of pregnancies in women
with gestations of up to nine weeks LMP (since
last menstrual period). However, because of
expense, commercial complexities, and the political climate surrounding the production and distribution of mifepristone, this drug may not be
widely available for years, leaving women in
many countries without access to medical abortion. Fortunately, researchers long ago acknowledged these potential barriers and for more than
a decade have explored alternate methods of
medical abortion, including administration of
misoprostol alone. Because misoprostol has been
available in many countries since the late 1980s,
off-label use (clinic-based and self-administered)
is now widespread for induction of both first- and
second-trimester abortion.

Synthesis of the Literature on Firstand Second-Trimester Abortion
Induction with Misoprostol Alone
John Jain, University of Southern California,
Los Angeles, CA, USA
Abortion induction in the first trimester
There is nearly a decade of published experience
on the use of misoprostol alone for first-trimester
abortion induction. Initial studies showed low efficacy1–3 (see Table 1), but Carbonell’s series of stud-

ies using vaginally administered misoprostol built
momentum for a misoprostol-alone regimen.4–7
Carbonell’s regimen included placement of premoistened tablets in the vagina, followed by a
three-hour recumbent period. Depending on the
study, 800-µg doses were repeated after 12, 24, or
48 hours for a maximum of four doses. At followup (14 days following the initial dosing), smaller
doses were given to women who had evidence of
incomplete abortion on ultrasound. Success rates
ranged from 64% to 94% (see Table 2).
Based on the regimen developed by
Carbonell, a series of small studies was conducted
at the University of Southern California (USC). In
all studies, four premoistened misoprostol tablets
(200 µg each) were inserted in the posterior vaginal fornices, and women remained recumbent for
30 minutes. At 24 hours, if a gestational sac was
seen on ultrasound, the 800-µg dose was repeated. Success rates were quite high, ranging from
83% to 88%, similar to the 94% success rate in a
similar study of first-trimester pregnancy termination with mifepristone and misoprostol.8 Many
more patients in the misoprostol-alone trial, however, displayed gastrointestinal side effects (such
as vomiting and diarrhea) and fever.
Following the success of the above studies, a
larger, randomized, placebo-controlled trial of 250
women comparing misoprostol alone to mifepristone and misoprostol was conducted in collaboration with the University of California, San Francisco.9 Women were given 200 mg mifepristone or
placebo followed two days later by 800 µg vaginal
misoprostol. If they failed to abort within 24 hours
following the initial dose they were given up to
two additional doses of 800 µg vaginal misoprostol. At 24 hours the misoprostol-only group had
72% and 86% success after one and two doses,
respectively, compared to 90% and 96%, respectively, in the mifepristone–misoprostol group.
Bugalho and colleagues explored whether
waiting one week to re-dose with misoprostol
women who had not completely expelled the products of conception would change the efficacy of
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TABLE 1 Misoprostol alone for first-trimester pregnancy termination, early studies
Study

Regimen

N

Gestational age (wks)

Success

400 µg oral misoprostol × 2
200 µg oral misoprostol × 2

100
100

9–12
9–12

11% (at 24 hrs)
9% (at 24 hrs)

200–600 µg oral misoprostol
Creinin and Vittinghoff (1994)
800 µg vaginal
misoprostol × 2 q 24 hrs

40
30

≤8
≤8

5%
47%

Rabe et al. (1987)1
Norman et al. (1991)2

3

misoprostol treatment.10 Women with gestations of
less than six weeks LMP were administered 800 µg
vaginal misoprostol. Women returned to the clinic
one week later for follow-up, and a second dose
was administered at that time if a gestational sac
was evident on ultrasound. At 24 hours following
administration of the first dose of misoprostol nearly three-quarters of the women (72%) had aborted,
which is comparable to rates of completion after
24 hours found in other medical abortion studies.
At the one-week follow-up only 13% of women
required a second dose. At 24 hours following redosing, the overall efficacy for the study had
increased from 87% to 92%. Waiting to administer
additional doses of misoprostol reduced the need
for re-dosing without decreasing success rates.
Given the reported high rate of side effects
with misoprostol-alone regimens, a recent study
by Jain and colleagues tested the effectiveness of
prophylaxis for reducing their frequency and
severity.11 The experimental group was given 500
mg acetaminophen to control fever and pain and 4
mg loperamide for diarrhea and vomiting as needed. While the frequency of fever and chills was high
in both groups, the incidence of diarrhea decreased
significantly with prophylaxis (from 44% to 23%,
OR 0.38, p=0.003). Moreover, prophylaxis was
associated with decreased use of opiates.
The possible advantage of premoistening
misoprostol tablets prior to vaginal administra-

tion has also been investigated, although not
thoroughly. In a study of misoprostol administered in combination with methotrexate, Creinin
and colleagues found no decrease in efficacy with
premoistened misoprostol.12 Ngai and colleagues
found that premoistened misoprostol tablets
inserted vaginally appeared slightly more effective than dry tablets, although the difference did
not reach statistical significance.13
The teratogenic potential of misoprostol is
of concern when treatment fails and a woman
chooses to continue her pregnancy. Several published reports indicate a possible association
between misoprostol exposure in utero and congenital defects. In one study, 50% of 96 infants
with Möbius syndrome had been exposed in
utero to misoprostol, as compared to 3% of
babies with neural tube defect.14 In another
study, Orioli and Castilla found that the frequency of limb and extremity malformation was
higher in exposed neonates, but did not find an
increase in Möbius syndrome.15 None of the
published reports describes a consistent pattern
of anomalies or a highly plausible mechanism
of teratogenicity. Although these studies do not
predict an absolute risk of congenital anomalies
in infants exposed in utero to misoprostol, in
the event of a failed abortion with misoprostol,
surgical completion of the abortion is strongly
recommended.16

TABLE 2 First-trimester induced abortion with misoprostol, studies by Carbonell and colleagues
Gestational
age (wks)

N

Regimen

Success
(% on day 7)
(95% C.I.)

Carbonell et al. (1997a)

4

≤ 10

141

800 µg vaginal misoprostol × 3 q 48 hrs

94 (90–98)

Carbonell et al. (1997b)

5

Study

≤9

175

800 µg vaginal misoprostol × 3 q 48 hrs (if necessary)

92 (87–96)

Carbonell et al. (2001)

6

10–12

150

800 µg vaginal misoprostol × 3 q 24 hrs

84 (77–89)

Carbonell et al. (2000)

7

≤9

90

600 µg vaginal misoprostol × 3 q 24 hrs

64 (53–74)
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TABLE 3 Side effects reported following second-

trimester abortion induction with misoprostol (N=180)*
Side effect

% (n)

Fever
Vomiting
Diarrhea
Moderate pain
Severe pain

13 (24)
6 (10)
2 (3)
55 (99)
16 (29)

* Unpublished results from studies conducted by John Jain at USC.

Abortion induction in the second trimester
In the United States, the most widely used method
to terminate a second-trimester pregnancy medically is induction of labor with intravaginal administration of dinoprostone, an E2 prostaglandin. This
treatment is highly effective, but it is associated
with gastrointestinal side effects and chills. Like
most prostaglandins, dinoprostone requires refrigeration and is expensive.
A study conducted at USC comparing the use
of misoprostol (200 µg intravaginally every 12
hours) and dinoprostone (20 mg intravaginally
every three hours) for termination of gestations
between 12 and 22 weeks LMP found no statistically significant difference in success rates (81%
and 89% of abortions were complete within 24
hours, respectively).17 After 48 hours, success rates
in both groups were about 90%. These rates were
comparable to those found by Srisomboon and
Pongpisuttinun, who tested a regimen of 200 µg

misoprostol inserted into the cervix every 12 hours
for 48 hours.18 For both the misoprostol and dinoprostone arms in the USC study a shorter induction-to-abortion interval and a higher rate of complete abortion were associated with abortion of a
dead fetus. In contrast, in cases with live fetuses
use of misoprostol alone resulted in slightly fewer
successful completions. Vomiting and fever were
reported by fewer than 15% of women in the misoprostol group, and diarrhea was reported by only
2% (see Table 3).
Srisomboon and Pongpisuttinun,18 Herabutya
and colleagues,19 and Wong and colleagues20 have
published results of studies comparing different
dosing regimens and routes of administration for
misoprostol, but more work is necessary to determine the optimal route, dose, and dosing interval
(see Table 4).

First-Trimester Induced
Abortion in India: Studies
with Misoprostol Alone
Kurus Coyaji, K.E.M. Hospital, Pune, India
A series of three unpublished studies conducted
at K.E.M Hospital was designed to investigate the
efficacy and safety of misoprostol when used
alone for early pregnancy termination. Women
enrolled had gestations of less than eight weeks
LMP and sought medical pregnancy termination.
The first study, essentially a dose-finding study,
consisted of three study arms: (1) two oral 800-µg

TABLE 4 Efficacy of second-trimester abortion induction with misoprostol
Study

Status
of fetus

Success at
24 hrs (%)

Success at
48 hrs (%)

Mean inductionto-abortion
interval (hrs)

Regimen

N

200 µg vaginal misoprostol q 12 hrs

180

Live
Dead

89
63

94
85

12
20

Srisomboon and
Pongpisuttinun
(1998)18

200 µg cervicovaginal misoprostol q 12 hrs

50

Live or dead

54

92

28

Herabutya et al.
(2001)19

200 µg vaginal misoprostol q 12 hrs
400 µg vaginal misoprostol q 12 hrs
600 µg vaginal misoprostol q 12 hrs

51
50
50

Live or dead
Live or dead
Live or dead

45
62
62

71
82
96

45
33
22

400 µg vaginal misoprostol q 3 hrs
400 µg vaginal misoprostol q 6 hours

74
74

Live or dead
Live or dead

73
61

91
76

24
43

Jain (unpublished)

Wong et al. (2000)20
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TABLE 5 Dose-finding studies of misoprostol alone for

first-trimester abortion induction*
Regimen

Route

N

Complete
abortion (%)

1

800 µg × 2
400 µg × 4
600 µg × 1

Oral
Oral
Vaginal

4
5
11

75
60
54

2

800 µg × 2
800 µg × 1

Oral
Vaginal

9
6

56
50

3

800 µg × 1 or 2

Vaginal

47

83

Study

* Unpublished results from studies conducted by Kurus Coyaji and the Population Council at
K.E.M. Hospital, Pune, India.

doses six hours apart, (2) four 400-µg oral doses
three hours apart, and (3) one 600-µg vaginal dose.
The second study compared two 800-µg dose regimens: (1) two oral doses six hours apart, and (2)
one vaginal dose. These two studies were discontinued when it became apparent that success rates
were under 75% for each arm (see Table 5).
In a third study, a regimen of 800-µg misoprostol, premoistened and inserted vaginally,
demonstrated a significantly higher success rate.
Nearly 83% of women (39 of 47 subjects) aborted
completely (the rate was 87% with protocol
violators excluded). In this study, although a
majority of the women reported experiencing
chills (75%), fever (55%), and gastrointestinal
symptoms (47%), acceptability was high. In fact,
all of the women who had a successful abortion
said they would recommend the method for pregnancy termination to a friend and 93% said they
would choose it again (see Table 6).

The results of this series of studies conducted
at K.E.M. Hospital provide evidence that misoprostol can be used as a stand-alone method to
terminate early gestations. Fine-tuning the regimen might further enhance the success rate.
Additional doses of misoprostol could also be
tried in women who have excessive bleeding.
There is also good evidence that misoprostol can
terminate effectively gestations in the second and
third trimester. Research on late-first-trimester termination (9–13 weeks) with misoprostol, however,
is lacking. Therefore, in addition to refining the
regimen for early pregnancy termination with
misoprostol, exploring methods for late-firsttrimester termination is an important goal of
future research.

Life-Table Analysis to Estimate the
Efficacy of Misoprostol for FirstTrimester Pregnancy Termination
Bryna Harwood, University of Southern California,
Los Angeles, CA, USA
The efficacy of misoprostol alone for medical
abortion has not been estimated using consistent,
comparable, or appropriate methods. Indeed,
there are many factors that determine failure of
medical abortion. The purpose of the following
analysis is to determine the efficacy of misoprostol for medical abortion using a life-table analysis.
Survival analyses were performed for perfect and
typical use following administration of one, two,
and three doses of misoprostol. The definitions
and assumptions used for the analysis are outlined in Box 6.

TABLE 6 Side effects associated with the use of

misoprostol alone for first-trimester abortion induction
(N=47)*
Side effect

Chills
Fever
Heavy bleeding
Pain
Vomiting
Nausea
Diarrhea

The studies

n

%

35
26
30
29
11
4
7

74.5
55.3
63.8
61.7
23.4
8.5
14.9

* Unpublished data from third study at K.E.M. Hospital, Pune, India.

Between 1996 and 2001, five trials conducted at
the University of Southern California investigated
the use of misoprostol for pregnancy termination
in the first 56 days of pregnancy. Using the same
regimen described by Jain (see above) and
depending on the trial, women were offered either
two or three 800-µg vaginal doses of misoprostol
to terminate their early pregnancies. The overall
completed abortion rate was between 88% and
93% in these studies.
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Definitions and assumptions used for
life-table analysis
BOX 6

Success

Complete expulsion of a pregnancy without need for curettage

Intervention

A repeated dose of misoprostol or uterine
curettage

Method failure

Intervention required

Elective failure

Subject exited protocol by choice

Perfect use

For measurement of perfect-use efficacy,
subjects exiting the protocol by choice
were censored at the time of exit and
therefore were no longer included in the
denominator

Typical use

For measurement of typical-use efficacy,
all subjects were included in the denominator, even those who exited the protocol
by choice

Pregnancy disruption For measurement of pregnancy disruption,
all subjects who experienced either a complete or an incomplete abortion were
included in the numerator

Results
Records of 365 women who had participated in
these trials were examined. Across the trials the
overall abortion rate was 89%. That rate rose from
79% after one dose to 89% after two doses, and
after the third dose efficacy increased to 91%.
Overall intervention rate was 9%; of that rate, the
rate intervention for subjects who requested to opt
out of the protocol was only 3%. Mean time to
abortion was 2.9 days (see Table 7).
The appearance of the uterus and the extent
of endometrial thickening post–medical abortion
were also evaluated using life-table analysis. The
literature considers normal an endometrial thickness of 15 mm or less for patients postabortion. In
the life-table analysis endometrial thickness for
women who had a successful abortion returned to
“normal” after about ten days. Analysis of the
data suggests that ultrasound follow-up is appropriate within two weeks of medical abortion, and
it should be performed no sooner than three days
following the final dose of misoprostol. Gravidity
greater than 1 seemed to be a significant predictor for abortion success in both multiple regression models and life-table analysis.

TABLE 7 Life-table analysis of the efficacy of misoprostol

when used alone for first-trimester abortion induction (%)
Misoprostol doses (800 µg)

One dose
Perfect use
Typical use
Disrupted pregnancy
≤ 2 doses
Perfect use
Typical use
Disrupted pregnancy
≤ 3 doses
Perfect use
Typical use
Disrupted pregnancy

Day 1

Efficacy
Study end (Day 28+)

72.1
72.1
81.4

76.9
76.8
90.8

72.1
72.1
81.4

88.5
87.7
95.2

72.1
72.1
81.1

90.8
89.8
96.9

Second-Trimester Induced
Abortion in Thailand: Studies
with Misoprostol Alone
Yongyoth Herabutya, Ramathibodi Hospital, Bangkok, Thailand
Before 1990, hypertonic saline solution was the
only method used for second-trimester pregnancy
termination at Mahidol University. Between 1990
and 1994 investigators began to explore using
prostaglandins, including Prostin® and misoprostol. Since 1995 misoprostol has been the sole
method used for pregnancy termination at
Mahidol University.
A dose-finding study conducted at the university between 1994 and 1996 compared three different doses of misoprostol (200, 400, and 600 µg)
administered vaginally every 12 hours for 48 hours
for termination of gestations between 14 and 24
weeks LMP.21 All regimens demonstrated greater
than 90% efficacy, with the highest dose (600 µg)
demonstrating the greatest success (96%) at 48
hours (see Figure 2). Side effects—including fever,
nausea, vomiting, diarrhea, and pain (as measured
by need for analgesia)—reported by women
appeared to increase with increasing doses of
misoprostol. Differences among dose groups, however, were not statistically significant (see Table 8).
Based on these results, a second, larger study
of 172 women tested a regimen of 600 µg vaginal
misoprostol every 12 hours as needed for termination of second-trimester gestations.22 In this study,
there was no difference in either the mean time to
abortion or the 48-hour completion rate between
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Cumulative abortion rate among women
treated with various vaginal misoprostol doses for
termination of gestations between 14 and 24 weeks21
FIGURE 2

100
80
% of cases completed

10

60
40
20
0
0

24

48

72

96

120

Hours following initial vaginal misoprostol dose
200 µg

400 µg

intervals appear to be associated with more frequent reports of side effects, such as fever, vomiting, nausea, and diarrhea (see Table 10).
In a separate study, which tested three regimens
(400 or 600 µg vaginal misoprostol every six hours
or 800 µg vaginal misoprostol every 12 hours), the
incidence of fever and the need for analgesia increased. This study showed, however, no difference
in outcomes among the three regimens tested.
Among women undergoing second-trimester
terminations with misoprostol, those who had had
a previous cesarean section (n=32) and those who
had not (n=387) experienced similar rates of complete abortion, abortion within 24 and 48 hours,
and mean days of bleeding.

Summary
600 µg

First-trimester induced abortion with
misoprostol alone
nulliparous and multiparous women. Gestational
age, however, was significantly related to the
induction-to-abortion time, with earlier gestations
exhibiting a longer induction-to-abortion timeframe. Similar to the initial dose-finding study,
complications and side effects were not severe.
Comparing the results of three studies19,20,22
that explored a range of doses from 400 to 800 µg
given vaginally every 3–12 hours suggests that, at
48 hours, 600 µg every 6 hours appears to be the
most effective dose for termination of pregnancies
between 14 and 24 weeks’ gestation. The completion rates with the misoprostol regimens tested
were as high as 97% (see Table 9). Additionally,
gravidity was not significantly associated with
either mean time to abortion or the completion
rate at 48 hours. Higher doses and shorter dosing

TABLE 8 Side effects following three vaginal misoprostol

regimens for second-trimester abortion induction 21
% experiencing side effect with
misoprostol q 12 hrs (n)
200 µg
400 µg
600 µg
(n=51)
(n=50)
(n=50)

Side effect
o

Temperature >38 C
Nausea/vomiting
Diarrhea
Intramuscular analgesia
Incomplete abortion

0
4 (2)
0 (0)
16 (8)
35 (18)

2 (1)
12 (6)
6 (3)
16 (8)
28 (14)

28 (14)
20 (10)
22 (11)
22 (11)
22 (11)

Studies indicate that misoprostol alone can be
highly effective when used for first-trimester termination. Regimens can have minimal side effects,
and can be simple to use, feasible for introduction
into a range of delivery settings, and desirable to
women. Among the regimens tested, 800 µg vaginal misoprostol appears be the best dose, yet the
timing and number of doses necessary to achieve
maximal efficacy is not yet clear. There is evidence
that re-dosing can increase the likelihood of complete abortion, and by waiting a week or two to redose, fewer women will require a second or third
dose. There may be no benefit to frequent or
immediate re-dosing (i.e., in the first 24–48 hours
after the initial dose). Finally, while most of the
studies explored vaginal administration of misoprostol, oral regimens may also be effective and
preferable for some women.
Factors to consider in creating a usable regimen are the efficacy and complexity of the regimen and the severity of side effects and their
impact on patient acceptability. Future goals for
developing the method include reducing the pain
women experience and the incidence of side
effects, particularly gastrointestinal complaints.
However, while many providers are concerned
about reducing gastrointestinal side effects related
to use of misoprostol, there is little evidence that
these particular side effects correlate with
decreased acceptability. In fact, the most important
predictors of finding the procedure acceptable are
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TABLE 9 Comparison of effectiveness of vaginal misoprostol alone for second-trimester abortion induction19,20,22

Mean misoprostol dose (µg)
Induction-to-abortion interval (hrs)
Complete abortion rate at 24 hrs (%)
Complete abortion rate at 48 hrs (%)

400 µg
q 3 hrs
(n=74)

400 µg
q 6 hrs
(n=74)

Misoprostol regimen
600 µg
q 6 hrs
(n=52)

2,021
15.2
73.0
90.5

1,546
19.2
60.8
75.7

2,239
21.0
73.1
96.8

600 µg
q 12 hrs
(n=172)

800 µg
q 12 hrs
(n=76)

1,405
24.1
68.6
89.5

1,684
19.8
78.9
92.1

TABLE 10 Comparison of side effects following use of vaginal misoprostol alone for second-trimester abortion induction19,20,22

Temperature >38°C (%)
Nausea/vomiting (%)
Diarrhea >3 days (%)
Need for intramuscular analgesia (%)

400 µg
q 3 hrs
(n=74)

400 µg
q 6 hrs
(n=74)

32.4
10.8
5.4
33.8

12.2
12.2
2.7
36.5

success with the method, satisfaction with the
quality of care provided, and low levels of pain.
Analgesic, antidiarrheal, and antiemetic medications are all useful for helping women manage the
procedure. Most important, greater attention
should be paid to improving efficacy of the method and reducing its complexity.
Finally, it is important to explore what women
are willing to tolerate in terms of side effects and
failure rates. Most researchers and providers
believe that treatment with mifepristone–misoprostol is superior to misoprostol alone for termination
of first-trimester pregnancies. In several studies,
however, misoprostol-alone regimens have
demonstrated success rates comparable to those
of mifepristone–misoprostol regimens. For some
women a 90% or even an 80% chance of avoiding
a surgical procedure is highly desirable. Therefore,
in countries where mifepristone is not available
(i.e., the majority of countries in the world) misoprostol alone offers an important, viable alternative to surgery for first-trimester abortion.

Second-trimester induced abortion with
misoprostol alone
Misoprostol can also be used for medical termination of second-trimester pregnancy. While misoprostol-alone regimens for abortion induction in
the second trimester have been shown to be safe

Misoprostol regimen
600 µg
q 6 hrs
(n=52)

59.6
5.8
26.9
30.8

600 µg
q 12 hrs
(n=172)

800 µg
q 12 hrs
(n=76)

41.3
14.6
20.3
17.4

71.1
6.6
10.5
27.6

and effective, total dose, dosing interval, and route
of administration have not been clearly established. Because the sensitivity of the uterus to
prostaglandins increases dramatically over the
course of the second trimester, regimens should
vary by gestational age. In addition, fetal status
(e.g., whether the fetus is live or dead at the start
of the procedure) may alter uterine sensitivity to
misoprostol, which may influence regimens. These
issues should be studied further.
The risk of uterine rupture increases for women with advanced gestations (i.e., those greater
than 16 weeks LMP). Caution is also advised when
treating women who have had previous cesarean
deliveries. Use of misoprostol for termination of
advanced gestations is not recommended for
women with either classical-vertical or low-vertical
incisions. For women with low-transverse incisions, termination with misoprostol may be safe.
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Uterine Evacuation After
Pregnancy Failure
Approximately 10%–20% of clinically recognized
pregnancies are not carried to term, with most failures occurring within the first 12 weeks of gestation.1 Early failures often resolve spontaneously
without treatment. Providers—often without
regard for clinical necessity—have typically resorted to surgical interventions to quickly resolve
incomplete or missed abortions, risking uterine
perforation, cervical tears, infection, and bleeding.
Only recently have expectant management (i.e.,
not treating women immediately upon presentation) and noninvasive (i.e., medical) techniques
begun to replace surgical intervention for pregnancy failure. Expeditious resolution of pregnancy failure may be desirable for psychological and medical reasons, with safe and effective noninvasive
treatment being particularly desirable. Given its
pharmacological properties, misoprostol has
emerged as a promising candidate to fill this role.
For pregnancy failure in the second and third
trimesters (usually referred to as intrauterine fetal
death, or IUFD) either labor is induced and the
fetus is delivered vaginally or dilation and evacuation (D&E) is performed, depending on gestational
age. As with treatment of early pregnancy failure,
there is no true gold standard for treatment of
IUFD, and researchers continue to explore new
methods.

Misoprostol and Miscarriage
Salina M.W. Pang and Tony K.H. Chung, Chinese University
of Hong Kong, Hong Kong, China
In Hong Kong, surgical evacuation of retained
products of conception (POCs) has been considered the gold standard of treatment for women
presenting with spontaneous abortions. Patients
undergoing such procedures in the past have
occupied approximately 18% of gynecology beds
at the Prince of Wales Hospital at the Chinese
University of Hong Kong. The development of
transvaginal ultrasound imaging, however, has
allowed for use of a nonsurgical protocol for evacuation of retained POCs (see Figure 3).
Pilot studies conducted at the Prince of Wales
Hospital indicated that a one-to-two-day course of
treatment with a prostaglandin (either misoprostol
or gemeprost) might be an alternative to surgical

Protocol for management of incomplete or
missed abortion developed at the Chinese University of
Hong Kong
FIGURE 3
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intervention. Based on this premise, a series of
small observational studies with misoprostol were
conducted at the hospital. Results demonstrated
that in 50% of cases treated with misoprostol
retained POCs were expelled without surgery.
A randomized, placebo-controlled trial in 767
subjects subsequently compared surgery and treatment with one dose of 800 µg misoprostol for
management of incomplete abortion.2 Results from
the trial indicated that patients treated with misoprostol had fewer short- and long-term complications, although the average duration of treatment
was longer in the misoprostol group. This latter difference, however, is probably due to the study protocol, which required all patients to be hospitalized
until retained POCs were expelled or evacuated
surgically (although in actual medical practice,
patients treated with misoprostol typically would
not require hospitalization). The average number of
days of bleeding was similar between the two
groups (9.1 days for misoprostol vs. 9.3 for surgery; p=0.48). There were higher rates of infection
and need for a secondary evacuation in the surgical group compared to the misoprostol group (see
Table 11). However, women who underwent surgical evacuation after misoprostol treatment experienced no complications. This last result is of particular note, as the cervical-priming effect of misoprostol might reduce the rate of complications following any necessary surgical evacuation.
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TABLE 11 Complications following treatment of incom-

plete and missed abortion with surgery or misoprostol

2

Surgical Treatment with
evacuation
misoprostol
(N=470)
(N=297) P-value

Treatment complications

Uterine perforation (n)
Cervical laceration (n)
Hysterectomy (n)

3
2
1

0
0
0

0.21
0.34
0.59

8
11
1
1

3
4
2
0

0.31
0.24
0.34
0.59

27 (5.7%)

9 (3.0%)

0.06

Short-term complications

Secondary evacuation (n)
Pelvic infection (n)
Missed ectopic pregnancy (n)
Missed molar pregnancy (n)
Total complications

Following the success of that trial, a second
randomized, placebo-controlled trial of 201 women
was conducted to compare the efficacy and side
effects of vaginal and oral misoprostol in the management of incomplete abortion.3 An 800 µg dose of
misoprostol was administered either vaginally or
orally to women presenting with retained POCs.
A second dose was repeated four hours later if the
POCs had not been expelled. Rates of complete
uterine evacuation were similar in the two groups
(64.4% following oral administration of misoprostol
vs. 61.1% following vaginal administration). There
was significantly less diarrhea among vaginal misoprostol users compared to those who took the medication orally (13.6% vs. 65.3%, p<0.001). No other
significant differences in side effects were observed.
This series of studies indicates that medical
management of incomplete abortion with misoprostol, given either orally or vaginally, is a safe
and effective alternative to surgical evacuation.
Treatment-related complications occur less frequently in women treated with misoprostol than in
those treated surgically. In addition, treatment with
misoprostol reduced the need for surgery as well
as the frequency of complications in cases requiring subsequent surgical completion.

Misoprostol and the Management
of Intrauterine Fetal Death (IUFD)
in the Second and Third Trimesters
Hazem el-Refaey, Chelsea and Westminster Hospital,
London, UK
Standards for the management of IUFD in the
second and third trimester are not well specified

in the literature; however, some guidance is available. First, mifepristone combined with misoprostol, where available, is commonly used to manage
IUFD. Second, protocols for management have
been adapted primarily from experience with second- and third-trimester pregnancy termination in
patients with either live or dead fetuses; protocols
have not been specifically developed for patients
with IUFDs.
The use of mifepristone in combination with
misoprostol for the induction of second- and thirdtrimester terminations in women with and without
IUFD is fairly well established.4–11 However, it has
not been established whether mifepristone is an
important adjunct to treatment with misoprostol or
whether misoprostol could be used by itself.
Mifepristone disrupts the decidua, ripens the
cervix, and, perhaps most important, increases the
sensitivity of the uterine myometrium to exogenous prostaglandins. In addition, treatment with
mifepristone may be associated with fewer overall
side effects, which may explain why a combined
therapy of mifepristone and misoprostol, as
opposed to misoprostol alone, has become popular in the management of second- and thirdtrimester terminations.
Reducing the duration of treatment for women
who have experienced an IUFD is important, and
the results of a recent study that explored two regimens for second- and third-trimester pregnancy
termination called into question the advantage of
mifepristone with misoprostol over misoprostol
alone. El-Refaey and Templeton compared the
induction-to-abortion interval in women receiving
either mifepristone or a placebo prior to administration of misoprostol for second- or thirdtrimester pregnancy termination in cases where
fetuses were either live or dead. Among those
women who had experienced IUFD prior to the
procedure, the use of mifepristone demonstrated
no significant advantage over misoprostol alone
with regard to time to abortion.10 Given these
results a misoprostol-alone regimen may be
preferable as it eliminates the 24–48-hour waiting
period between the administration of mifepristone
and misoprostol, effectively decreasing the length
of the procedure, and is much less expensive.
The route of misoprostol administration may
influence acceptability of regimens for secondand third-trimester terminations. Research has
indicated that women tend to prefer oral misoprostol, in part because they do not have to be
subjected to vaginal examination. Also, in later
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pregnancy termination the release of amniotic
fluid may decrease misoprostol’s bioavailability
when administered vaginally. Nonetheless, elRefaey and Templeton suggest that in the majority
of patients a combined vaginal/oral misoprostol
regimen may be both highly effective and acceptable because such a regimen combines the pharmacokinetic properties of the two routes (which
together may confer the maximal benefit) and
reduces the number of times a woman may be
required to undergo vaginal examination and
administration of drug.
At the University of Aberdeen, a randomized,
controlled trial tested such a regimen. Seventy
women with either live or dead fetuses who sought
second- or third-trimester uterine evacuation were
given 600 mg oral mifepristone followed 24–48
hours later by 600 µg vaginal misoprostol.10 After
the initial dose of misoprostol, women were randomized to receive additional doses of 400 µg misoprostol orally or vaginally every three hours. The mean
induction-to-abortion interval was the same for
both groups (about six hours), and most women
required only one or two doses of misoprostol. The
frequency of gastrointestinal side effects, however,
was high and not comparable to similar studies,
with 57% of women in both groups combined
reporting vomiting and 29% reporting diarrhea.

Summary
Treatment of incomplete and missed abortion
Research suggests that misoprostol may be an
important alternative to surgical interventions in
the treatment of missed or incomplete abortion.
Although use of misoprostol for evacuating
retained POCs may not be 100% effective, and
therefore some women will still require surgical
evacuation, the cost and simplicity of offering
misoprostol as a “first-line” treatment has tremendous benefits. First, misoprostol can be used
where access to surgery is limited. Second, it can
greatly reduce the burden of surgical procedures
on hospitals, in both cost and time. Third, acceptability research indicates that many women prefer
avoiding surgery when possible. Nonetheless, if
women with missed or incomplete abortions were

managed expectantly (i.e., not given any treatment
on intake), many abortions would resolve without
treatment. Research to explore the benefits and
risks of expectant management compared to both
surgical and medical management is warranted.
Based on medical abortion research, we know
that success with a method is highly correlated to
satisfaction. We also know that many women will
choose a medical method to avoid surgery. Yet we
do not know what level of efficacy women would
find acceptable for treatment of incomplete or
missed abortion with misoprostol. Furthermore,
the optimal regimen may not have been discovered, as there has been no true pharmaceutical
development testing a range of dosages, timing,
and route of administration. Finally, to maximize
efficacy it may be important to develop different
regimens for treatment of incomplete versus
missed abortion with misoprostol, and there is
some evidence that misoprostol may not be equally effective in these two different circumstances.
Although further research may help refine regimens to optimize treatment, guidelines based on
published data could be developed, as there is evidence that more providers are beginning to offer
misoprostol as an alternative to surgical evacuation.

Treatment of intrauterine fetal death
Misoprostol is also a promising treatment for late
pregnancy failure, often referred to as IUFD.
Although regimens tested appear effective, there
are few published studies and, in all studies, sample sizes are small. Additional data could help
direct the development of treatment guidelines. In
particular, published studies on misoprostol for
treatment of IUFD have tested only one regimen
for a very wide range of gestations. Therefore,
despite tremendous physiological differences in
the uterus at different stages of gestation, failures
of both early-second-trimester and late-thirdtrimester gestations are treated similarly. It may be
more appropriate to have regimens based on narrower gestational age limits. Also, because the literature reports only on regimens in which misoprostol is administered vaginally, it would be useful
to explore regimens that make use of other routes
of administration.
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Labor Induction with
Misoprostol

Review of Labor Induction with
Misoprostol: Route of Administration,
Efficacy, Safety, and Potential Concerns

The frequency of labor induction has varied historically as well as geographically. For example,
in the 1970s in the United Kingdom nearly 50%
of labors were induced. In the 1980s, rates fell
considerably and then rose slightly in the 1990s.
That rise may have been due in part to a
Canadian study on post-term pregnancies published in 1992 indicating that labor induction
reduced the rate of cesarean sections and did not
increase neonatal morbidity.1 In recent years
changes in the indications for induction (i.e., recommendations by professional organizations
such as the American College of Obstetricians and
Gynecologists, the Royal College of Obstetricians
and Gynaecologists, and the Society of Obstetricians and Gynaecologists of Canada) may be
responsible for lower rates of inductions in some
countries.
Compared to women who experience spontaneous deliveries, a higher percentage of all women
whose labors are induced require cesarean sections. One reason for this is that many women
with medical indications for inductions are not at
term and have highly unfavorable cervixes (i.e.,
Bishop scores <4). Nonetheless, labor induction
may be preferable to an immediate cesarean section and can result in better outcomes for mother
and infant. Methods of induction include amniotomy (deliberate rupture of the fetal membranes,
carried out only when the cervix is favorable) and
administration of either oxytocin (usually administered after amniotomy) or prostaglandins (usually
series E analogs).

Allan Templeton, University of Aberdeen, Aberdeen, UK
In 1997, Sanchez-Ramos published a meta-analysis
of labor induction with misoprostol.2 His analysis
showed that, compared to other prostaglandins,
oxytocin, or placebo, induction with misoprostol
led to shorter induction-to-delivery intervals and
lower rates of cesarean section with no difference
in neonatal outcomes (such as admission to a
neonatal intensive care unit). However, induction
with misoprostol resulted in slightly higher rates
of uterine tachysystole (more than five contractions every ten minutes for at least 20 minutes)
and uterine hyperstimulation (a contraction lasting
at least two minutes). The differences were not statistically significant. From this review, it appears
that misoprostol is effective at inducing labor, yet
certain precautions should be taken.*
Safe and effective doses of misoprostol for
labor induction are much lower after 24 weeks’
gestation, perhaps related to shifts in progesterone
levels. In a randomized comparative trial completed at Aberdeen Maternity Hospital, a low dose of
misoprostol (50 µg given vaginally every four hours
to a maximum of 200 µg) resulted in a significant
reduction in the median induction-to-delivery interval and in the need for oxytocin augmentation
compared to administration of dinoprostone vaginal gel (1 mg every six hours to a maximum of 3
mg).3 Moreover, women given misoprostol delivered
within 12–24 hours and after only one dose (see
Table 12). There were no adverse neonatal events.
In order to observe possible rare adverse events,
however, additional large trials would be required.

* In 1999 the American College of Obstetricians and Gynecologists published a specific guideline on induction of labor with misoprostol (see Box 7, p. 22). The Royal College of Obstetricians and Gynaecologists and the Society of Obstetricians and Gynaecologists of
Canada also recently published guidelines on induction that are more general but include misoprostol.

TABLE 12 Misoprostol compared to dinoprostone for labor induction at term3

Induction-to-delivery interval (mean hrs)
Women requiring one dose (%)
Need for oxytocin augmentation (%)

Misoprostol 50 µg q 4 hrs
(max 4 doses) (N=105)

Dinoprostone 1 mg q 6 hrs
(max 3 doses) (N=106)

P-value

14.4
77
21

22.9
49
47

<0.00001
<0.0001
<0.0001
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Indeed, while the extensive published literature indicates that misoprostol is effective for
inducing labor, dosage is a key issue that remains
unresolved both practically and theoretically. The
benefits of a lower dose of misoprostol (i.e., 25–50
µg), particularly in relation to reduced rates of
uterine hyperstimulation, have become clear. The
delivery of that lower dose, however, remains an
issue, as only 100- or 200-µg tablets are available.
Oral suspensions of the drug are an alternative
dosing strategy, but it is difficult to deliver exact
doses reliably. Similarly, splitting tablets is not a
precise method of delivering lower doses.
The literature also does not indicate the appropriate route of administration. A trial recently completed at Aberdeen Maternity Hospital compared
two doses of oral misoprostol, 50 µg and 100 µg,
repeated every fours hours for a maximum of five
doses.4 Results indicated no difference in the number of cesarean deliveries for fetal distress or in
neonatal outcomes between the two dose groups.
Although the mean induction-to-delivery interval
was longer in the 50-µg group (26.8 hours in the
100-µg group vs. 33.7 hours in the 50-µg group),
this difference was not statistically significant. The
percentage of failed inductions, however, was significantly higher in the low-dose group (12.7% vs.
4.8%). The study suggests that oral misoprostol
administration may be safe and effective, and that
a 100-µg dose may be as safe and effective as a 50µg dose. Moreover, because 100-µg tablets are the
smallest dose available, and the rate of failed
induction was lower in the 100-µg group with no
increase in adverse events such as uterine hyperstimulation, this route may be preferred for labor
induction regimens with misoprostol. Larger trials,
however, are warranted to explore further the safety and efficacy of this regimen (see Table 13).

It is important to consider the differences
between oral and vaginal administration of misoprostol. The fact that vaginally delivered drug
reaches the target tissues before being metabolized by the liver results in a substantial and perhaps important difference in the pharmacokinetics
of the two routes. The local effects of the drug on
the uterus, including on the cervix, may also differ
between the two routes. No study comparing
these effects, however, has been published, and
they are not well understood.
Induction of labor by sublingual misoprostol
may be a viable alternative to either vaginal or oral
administration as it theoretically combines the
liver-bypass effect seen with vaginal administration with the safer level of uterine stimulation seen
with oral administration. The results of a study,
also recently completed at Aberdeen Maternity
Hospital, comparing sublingual to oral administration indicate that the induction-to-delivery interval
was shorter with the sublingual route.5 There were
no differences in neonatal outcomes between the
two groups, but there was one case of hyperstimulation with sublingual misoprostol (see Table 14).

Medically Indicated Induction of
Labor with Misoprostol and
Induction of Labor in Women with
Previous Cesarean Section
Luis Sanchez-Ramos, University of Florida,
Jacksonville, FL, USA
Many clinicians have begun to use misoprostol to
induce labor in order to improve obstetric and
neonatal outcomes for women with medical indications for labor induction. Prelabor rupture of

TABLE 13 Comparison of 50 µg and 100 µg oral misoprostol for labor induction at term4

Outcome

Misoprostol doses (n ±S.D.)
Oxytocin augmentation (%)
Cesarean delivery (%)
Cesarean deliver for fetal concerns (%)
Uterine hyperstimulation (%)
Induction-to-delivery interval (hrs ±S.D.)
Delivery within 24 hours (%)
5-minute Apgar (median [range])
NICU admission (%)

50 µg q 4 hrs
(max 5 doses)
(n=126)

100 µg q 4 hrs
(max 5 doses)
(n=125)

Mean difference/
relative risk
(95% C.I.)

2.3 ±1.5
53.2
26.2
6.3
0.0
33.7 ±26.2
44.0
9 (6–9)
9.5

1.8 ±1.2
46.5
22.4
8.8
1.6
26.8 ±19.0
53.6
9 (6–9)
12.0

0.5 (0.2–0.8)
0.9 (0.7–1.1)
0.9 (0.6–1.3)
1.4 (0.6–3.3)
5.0 (0.2–108)
6.9 (0.4–13)
1.5 (0.8–2.6)
—
1.3 (0.6–2.6)
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TABLE 14 Comparison of sublingual and oral misoprostol for labor induction at term5

Outcome

50 µg sublingual
q 4 hrs (max 5 doses)
(n=125)

100 µg oral
q 4 hrs (max 5 doses)
(n=125)

Mean difference/
relative risk
(95% C.I.)

1.5 ±0.9
46.4
24.8
11.2
1.6
21.8 ±14.6
62.8
0.8
12.0

1.6 ±0.9
51.6
25.8
1.6
0.0
24.1 ±16
59.0
4.0
9.5

0.1 (–0.13–0.33)
0.9 (0.7–1.2)
1.0 (0.6–1.5)
1.3 (0.6–2.7)
1.0 (0.1–6.9)
2.3 (–2.2–6.7)
1.1 (0.6–2.1)
0.2 (0.02–1.7)
1.3 (0.6–2.6)

Misoprostol doses (n ±S.D.)
Oxytocin augmentation (%)
Cesarean delivery (%)
Cesarean delivery for fetal concerns (%)
Uterine hyperstimulation (%)
Induction-to-delivery interval (hrs ±S.D.)
Delivery within 24 hours (%)
5-minute Apgar <7 (%)
NICU admission (%)

membranes at term and severe pre-eclampsia
remote from term are two common indications for
which misoprostol has been tested. Misoprostol
has also been used to induce labor in women
attempting vaginal delivery after cesarean section.

Induction of labor for prelabor rupture of
membranes at term
Prelabor rupture of membranes at term (term-PROM)
occurs in approximately 10% of term pregnancies,
and 95% of affected women deliver within 72
hours without intervention. It is not clear from the
literature whether expectant management or labor
induction leads to better overall outcomes for mother and infant. Results from the TERMPROM study
demonstrated that expectant management resulted
in fewer cesarean deliveries, an equal number of
neonatal infections, and more maternal infections
compared to induction of labor.6 Results of the study
also indicated that women viewed induction of labor
more favorably than expectant management.
Six randomized trials of misoprostol for induction of labor following term-PROM studied deliveries of singleton pregnancies in cephalic presentation with comparable gestational ages.7–12 Women
with a history of previous cesarean section, multifetal pregnancy, infection, or who were in active
labor were excluded. The trials compared a range
of misoprostol doses and regimens to either oxytocin or placebo. The overall cesarean rate for
women treated with misoprostol was 11% compared to 13% in the control groups. This difference
was not statistically significant. Approximately
three-quarters of the women (73%) delivered after
a single dose of misoprostol (25–200 µg), and the

mean induction-to-delivery interval was 9.4 hours.
About one-quarter of the women (26%) required
augmentation with oxytocin (see Table 15).
Comparing the results of studies by SanchezRamos and colleagues8 (which compared 50 µg
vaginal misoprostol to oxytocin infusion) and Wing
and Paul9 (which compared 25 µg vaginal misoprostol to oxytocin infusion), there do not appear
to be significant differences in the overall rate of
cesarean delivery or the frequency of cesarean
deliveries because of fetal heart rate abnormalities
following administration of either dose of misoprostol. The higher dose was associated with a
decreased induction-to-delivery interval and lower
frequency of infection, but an increased frequency
of tachysystole and uterine hyperstimulation (see
Table 16).
A significantly larger proportion of neonates
born after labors induced with the lower dose of
misoprostol were admitted to the neonatal intensive care unit (26% vs. 7% of neonates whose
labors were induced with the higher dose). This
difference may be related to the fact that, on average, the induction-to-delivery period following
induction with 25 µg vaginal misoprostol was
longer, or it may be due to varying NICU admission criteria in the two study hospitals. The percentage of neonates with Apgar scores <7 at five
minutes, however, was similar in both studies.
Labor induction with misoprostol in termPROM patients appears to be as effective and safe
as induction with oxytocin infusion. In addition,
the rate of cesarean section following induction
with misoprostol may be lower. Although several
effective regimens have been tested, data are not
sufficient to suggest an optimal dose and route of
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TABLE 15 Six randomized controlled trials of misoprostol for labor induction in women with prelabor rupture of

membranes at term
Misoprostol regimen

Comparison regimen

N

n

Route

Regimen

Cesarean
deliveries (%)

80

39

Oral

200 µg q 12 hrs

7.7

41

Placebo (vitamin B6)

7.3

Sanchez-Ramos et al.
(1997)8

141

70

Vaginal

50 µg q 4 hrs
(max 600 µg)

11.4

71

Oxytocin

12.7

Wing and Paul
(1998)9

197

98

Vaginal

25 µg q 6 hrs
(max 50 µg)

13.3

99

Oxytocin

17.1

Butt et al.
(1999)10

108

55

Oral

50 µg q 4 hrs

14.5

53

Oxytocin

13.2

Ngai et al.
(2000)11

80

40

Oral

100 µg q 4 hrs
(max 300 µg)

5.0

40

Oxytocin

7.5

Hoffmann et al.
(2001)12

96

47

Oral

100 µg q 6 hrs
(max 200 µg)

8.5

49

1 mg vaginal prostaglandin
E2 q 6 hrs (max 2 mg)
Placebo (vitamin C)

9.6

Study

Ngai et al.
(1996)7

administration. Increasing the dose of misoprostol
to more than 25 µg may lead to faster deliveries
but also to more unpredictable or uncontrollable
uterine stimulation. The effect of this tradeoff on
maternal and neonatal outcomes is unclear.

Severe pre-eclampsia remote from term
Remote from term, the unfavorable state of the
cervix makes uncomplicated vaginal delivery after
induction less likely than at term. Therefore, the
care of women with severe pre-eclampsia remote

TABLE 16 Comparison of 25 µg and 50 µg vaginal
misoprostol for labor induction in women with prelabor
rupture of membranes at term
Outcome

Wing and Paul Sanchez-Ramos et al.
(1998)9
(1997)8

Chorioamnionitis (%)
28.6
Interval to delivery
(min ±S.D.)
901 ±558
Tachysystole (%)
6.1
Uterine hyperstimulation (%)
0.0
Cesarean delivery (%)
13.3
Cesarean deliver for fetal
heart rate abnormalities (%)
4.1
5-minute Apgar score <7 (%)
2.0
NICU admission (%)
25.5

5.7
416 ±276
28.6
8.6
11.4
4.3
1.4
7.1

n

Agent

Cesarean
deliveries (%)

from term must take into account the risks of continuing the pregnancy and the risks of inducing
labor or performing a cesarean section. Unfortunately, there is little guidance for practice in the
published literature.
An unpublished retrospective analysis from
the University of Florida of the management of
severe pre-eclampsia remote from term compared
outcomes of cases of induced labor before (n=78)
and after (n=62) misoprostol became available for
use in labor induction in 1991 (see Table 17). Both
the frequency of cesarean delivery and the average time to delivery after misoprostol became
available were lower, although these differences
were not statistically significant. In fact, patients
with highly unfavorable cervixes (i.e., Bishop
scores <4) were more likely to be induced during
the period when misoprostol was available.
Analysis of unpublished data from a community
hospital compared outcomes of labor inductions
using misoprostol (n=114) and oxytocin (n=95) in
women with severe pre-eclampsia remote from
term. The frequency of cesarean delivery in the misoprostol group was higher than it was in the oxytocin
group (15% vs. 10%, p=0.29), although this difference
was not statistically significant. Delivery within 12
hours following induction was more common in
women who had been administered oxytocin (71%
vs. 47% of women in the misoprostol group,
p=0.007). The percentage of women with highly unfa-
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TABLE 17 Use of misoprostol to induce labor in women

with severe pre-eclampsia remote from term*
Outcome

Time period evaluated
1988–91
1992–96 P-value

Patients having labor induction (N)
41
44
Cesarean delivery (%)
46.3
29.5
Assisted vaginal delivery (%)
17.1
9.1
Vaginal delivery ≤ 24 hrs (%)
39.0
50.0
Induction-to-delivery interval (min) 945±740 1,078±674

0.12
0.17
0.90
0.26

*Unpublished data from a community hospital in Florida aggregated by Luis SanchezRamos at the University of Florida, Jacksonville.

vorable cervixes, however, was significantly higher in
the misoprostol group (69% vs. 54% in the oxytocin
group, p=0.03) and could have contributed to the
higher frequency of cesarean delivery and the longer
induction-to-delivery interval in that group.
In conclusion, misoprostol appears to be safe
and effective at inducing labor in women with
severe pre-eclampsia remote from term, but not
necessarily superior to oxytocin. More information
on this subject, controlling for cervical dilation,
would help guide practice.

Induction of labor in women previously
delivered by cesarean section
It is fairly common practice in the United States for
women who have previously delivered by cesarean section to attempt vaginal delivery subsequently, and most women attempting labor have a successful vaginal birth (referred to as vaginal birth
after cesarean, or VBAC).13 A major concern of
women attempting VBAC is uterine rupture, the
frequency of which varies with the type of cesarean scar. Rupture occurs in 0.2%–1.5% of women
with low-transverse scars, between 1% and 7% of
those with low-vertical incisions, and between 4%
and 9% of those with classical-vertical incisions.
It is uncertain whether induction of labor—as
opposed to spontaneous delivery—in women
attempting VBAC increases that risk. The literature
on this topic is inconsistent, particularly with
regard to comparability of study populations and
use of standard definitions for analysis (e.g., the
terms “cervical ripening,” “labor induction,” and
“labor augmentation” are often poorly defined).
There is also an important difference, not always
delineated, between complete rupture and dehiscence (i.e., partial separation of the uterine scar).

The former is far more serious as it is more likely
to lead to maternal and neonatal morbidity and
mortality. Finally, it is important to consider that
during elective repeat cesarean section (without a
trial of labor) there is also a risk of uterine rupture
(0.2% of deliveries), albeit lower than the risk associated with attempted VBAC.14
Determining whether uterine rupture (or
dehiscence) is more common among women with
previous cesarean sections induced with misoprostol as compared with other methods of induction or with spontaneous delivery would require a
very large randomized trial (according to one calculation such a trial would require 1,600 subjects
in each study arm). While a trial of this magnitude
has not been conducted, several smaller, uncontrolled trials have been completed. An unpublished
review of 15 studies of misoprostol induction in
women with previous cesarean section (ten articles and five abstracts) netted 641 cases in which
the frequency of scar disruption was 2.8%.
In a trial conducted at USC that enrolled 38
women attempting VBAC who received oxytocin
infusion or misoprostol, two patients in the misoprostol arm experienced scar disruption.15 The
overall frequency of scar disruptions was deemed
too high, and the trial was discontinued.
In an unpublished study at the University of
Florida, 72 women who had one or two previous
cesarean sections were enrolled and received
either 50 µg vaginal misoprostol every six hours
(n=37) or oxytocin infusion for induction of labor
(n=35). There was no difference between the
groups with regard to maternal demographics,
indications for prior cesarean sections, indications
for induction, frequency of failed induction, or
maternal postpartum complications. There were no
uterine ruptures in the misoprostol group and one
in the oxytocin group. There was one case of
dehiscence in the misoprostol group and four in
the oxytocin group.
Several small, randomized trials have compared spontaneous VBAC patients and women
with previous cesarean in whom labor was
induced (with oxytocin, dinoprostone, or misoprostol). A meta-analysis indicated that while
induction with oxytocin does not significantly
increase the risk of uterine rupture compared to
spontaneous labor, induction with prostaglandins
(dinoprostone and misoprostol) does. The evidence does not support use of misoprostol for
induction of labor in women attempting VBAC,
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TABLE 18 Comparison of safety of spontaneous delivery and labor induction with misoprostol in women with previous

cesarean attempting vaginal birth
Uterine ruptures per study group (n/N)
Study

Induction with misoprostol

Spontaneous delivery

Odds ratio (95% C.I.)

5/89
2/57
3/39
10/285

0/364
0/57
13/560
13/1,096

47 (2.6–867)
5.2 (0.2–110)
3.5 (0.9–13)
3.03 (1.3–7.0)

Plaut et al. (1999)16
Cunha et al. (1999)17
Butt et al. (1999)10
Total

particularly where oxytocin is available and widely
used (see Table 18).

Summary
Induction of labor with misoprostol appears to be
a safe and effective alternative to other modern
methods of labor induction, such as other prostaglandins or oxytocin. However, the way misoprostol stimulates contractions of the uterus may be
less predictable, and the frequency of tachysystole
and uterine hyperstimulation may be higher in
induction with misoprostol than with oxytocin.
The use of misoprostol seems appropriate for
induction of labor in women with term-PROM and
severe pre-eclampsia remote from term. It may
also be the preferred method for women with very
unfavorable cervixes. There are precautions for
use, however. The use of misoprostol in women
who are attempting VBAC is not recommended
because of a possible increased risk of uterine rup-

BOX 7 American College of Obstetricians and
Gynecologists (ACOG) guidelines for induction of labor with
misoprostol

“Given the current evidence, intravaginal misoprostol tablets appear
effective in inducing labor in pregnant women who have unfavorable
cervixes.” (ACOG Practice Guideline, November 1999)
• If misoprostol is to be used for cervical ripening or labor induction in the third trimester, one-quarter of a 100-µg tablet
(approximately 25 µg) should be considered for the initial dose.
• Doses should not be administered more frequently than every
3–6 hours.
• Oxytocin should not be administered less than 4 hours after the
last misoprostol dose.
• Misoprostol should not be used in patients with a previous
cesarean delivery or prior major uterine surgery.

ture or scar dehiscence. The frequency of uterine
rupture during an attempted vaginal birth in
women with previous cesarean varies by type of
uterine scar, and labor induction with misoprostol
may be safe in women with low-transverse scars,
although additional data are needed before making this recommendation.
Several professional obstetrician and gynecologist groups have developed guidelines for labor
induction with misoprostol (see Box 7). These
guidelines will need to be refined as new data
become available. In particular, new data may help
determine whether certain treatment criteria would
reduce the frequency of more serious maternal
and fetal/neonatal complications (see Box 8).
Several other issues warrant further exploration. For instance, the optimal dose and dosing
interval may not have yet been identified. Several
meta-analyses indicate that vaginal doses of 25–50
µg or oral doses of 50–100 µg are safe and effective. Published guidelines recommend vaginal
dosing, but the benefit of vaginal versus oral
administration has not been fully evaluated. It may

BOX 8 Major considerations for labor induction with
misoprostol

1. What dose should be used?
2. What is an appropriate dosing interval?
3. Is misoprostol use appropriate for women with prelabor rupture of
membranes?
4. Is misoprostol use appropriate for women who have had a prior
cesarean section?
5. Is oral administration of misoprostol appropriate?
6. Can misoprostol be used for outpatient cervical ripening?
7. What is the best mechanism for ensuring the delivery of
<100 µg doses?
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be that oral and vaginal administration are both
safe and effective, in which case the choice of
route may be left to the discretion of the patient
and provider. On the other hand, pharmacokinetic
differences in the two routes may mean that one is
safer or more effective than the other. These differences should be explored further—either with new
studies or through meta-analysis of existing data—
to improve guidelines for use. In addition, recent
studies have explored buccal and sublingual
administration of misoprostol. The potential benefits of these new routes of administration merit
further study and inclusion in meta-analyses, and
may warrant revision of treatment guidelines.
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Use of Misoprostol During
the Third Stage of Labor
The third stage of labor carries the highest risk of
mortality and morbidity for the mother because of
the potential for postpartum hemorrhage (PPH),
which accounts for about one-quarter of maternal
deaths worldwide.1 Hemorrhage requires prompt
treatment in order to avoid blood transfusions
and/or major surgical interventions. Prevention
and treatment of PPH can help decrease mortality
and morbidity rates in the postpartum period.
Agents traditionally used to treat PPH, such as
methylergometrine or oxytocin, may not be appropriate for use in a range of delivery settings and
sometimes are not effective. Misoprostol is a
promising alternative for treatment and prevention
of PPH in low-resource settings. It can also be used
in women with pre-eclampsia, as, in contrast to
other available prostaglandins, its use is not contraindicated in women with high blood pressure.2
Finally, misoprostol can be considered an adjunct
treatment when oxytocin and methylergometrine
fail to control hemorrhage.
The first study on the use of misoprostol for
the prevention of PPH was published by el-Refaey
and colleagues in 1996.3 Since then, the results of
nearly 20 more trials comparing misoprostol
(administered either orally or rectally) to placebo
and to standard treatments have been published.4–22 There are, however, significant methodological challenges to understanding the true
effectiveness of misoprostol for treatment and prevention of PPH. First, there is no gold standard
that can be used as an indicator for rates of PPH.
Typically blood loss is used as an indicator, yet its
measurement, most often by visual estimation, is
imprecise. Furthermore, there is no consensus on
the level of blood loss associated with negative
maternal outcomes, although amounts exceeding
500 mL or 1,000 mL have been used as study endpoints. Other indicators, such as mean change in
hemoglobin, mean blood loss, and need for additional oxytocics, have also been used as indicators
of PPH.
Second, while several large clinical trials have
been conducted on PPH, comparison of results is
difficult, as the studies employed different methodologies, definitions, and measurement techniques.
Some studies have investigated small samples,
with the result that the data are not sufficient to

draw conclusions about the benefit of misoprostol
over standard treatments for prevention or treatment of PPH.

Use of Misoprostol to Prevent
Postpartum Hemorrhage: The WHO
Third Stage of Labor Trial23
A. Metin Gulmezoglu, World Health Organization, Geneva,
Switzerland
PPH is a leading cause of maternal mortality and
morbidity. In many parts of the world in an effort to
reduce the incidence of severe hemorrhage, active
management of the third stage of labor recently has
become a standard aspect of obstetric care, and
misoprostol has emerged as one promising treatment alternative. A pilot trial, conducted in Thailand
and South Africa, determined that a 600-µg oral
dose of misoprostol ensures maximal efficacy with
acceptable tolerability.24 The subsequent WHO trial
was powered to compare the rates of two primary
outcomes in the two study groups: (1) postpartum
blood loss of 1,000 mL or more and (2) the need for
additional uterotonics. Secondary outcomes included postpartum blood loss of more than 500 mL,
need for blood transfusion, manual removal of the
placenta, delayed PPH (i.e., later than one hour
postpartum), and treatment for severe hemorrhage
(including bimanual compression and hysterectomy). Data on side effects were also collected.
Nine centers worldwide participated, enrolling
18,530 women (see Table 19 for participant characteristics). Women were randomized prior to labor,
but treatment packs were dispensed only when it
was certain that vaginal delivery would occur (i.e.,

TABLE 19 Characteristics of WHO trial participants

by study group

Maternal age (yrs) (mean ±S.D.)
Parity = 0 (%)
Parity ≥ 5 (%)
Gestational age <37 wks
Oxytocin or prostaglandin before
delivery (%)
Epidural analgesia (%)
Assisted vaginal delivery (%)
Perineal suturing (%)
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Misoprostol
(600 µg oral)

Oxytocin
(10 I.U.)

26.5 ±5.5
44.8
5.2
12.2

26.3 ±5.4
45.8
5.2
11.7

38.0
6.2
9.1
66.4

37.8
6.0
8.2
66.1
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TABLE 20 Primary and secondary outcomes of the WHO trial
Misoprostol (600 µg)

Oxytocin (10 I.U.)

Relative risk (95% C.I.)

P-value

4
15

3
11

1.39 (1.19–1.63)
1.40 (1.29–1.51)

<0.0001
<0.0001

20
0.8
2
0.4
0.9
0.8
0.04
0.04
0.02

14
1
2
0.3
0.9
0.7
0.09
0.05
0.02

1.44 (1.35–1.54)
0.74 (0.55–1.01)
1.02 (0.85–1.23)
1.19 (0.74–1.92)
1.05 (0.77–1.43)
1.15 (0.82–1.62)
0.50 (0.15–1.66)
0.80 (0.22–2.98)
1.00 (0.14–7.10)

<0.0001
0.06
0.88
0.54
0.81
0.48
0.39
1.00
1.00

Primary outcome

Blood loss ≥ 1,000mL (%)
Use of additional uterotonics (%)
Secondary outcome

Blood loss ≥ 500mL (%)
Need for blood transfusion (%)
Manual removal of placenta (%)
Delayed postpartum hemorrhage (%)
Exploration under general anesthesia (%)
Bimanual compression (%)
Hysterectomy (%)
Admission to intensive care (%)
Maternal death (%)

during the second stage of labor). 600 µg oral
misoprostol or 10 I.U. oxytocin given intramuscularly or intravenously (and matching placebo) was
administered after delivery of the baby and the cutting of the cord. Prior to participation in the study,
providers at all centers practiced some form of
active management of the third stage of labor.
The frequency of blood loss of 1,000 mL or
more was low in both groups, 4% in the misoprostol
group and 3% in the oxytocin group. Significant
intercenter variation, however, was observed.
Overall, additional uterotonics were more likely to
be administered to women in the misoprostol group
(15% vs. 11% in the oxytocin group). Both of these
aggregate differences were significant, and the relative risk was similar (about 1.4) (see Table 20).
The aggregate frequency of blood loss of 500
mL or more was also significantly different across
the two study groups (20% in the misoprostol
group vs. 14% in the oxytocin group). Few women
in either group required transfusions, yet fewer in

TABLE 21

the misoprostol group required transfusions than
in the oxytocin group. All other outcomes
appeared similar with respect to study group (see
Table 20). These outcomes were rare, however,
and the sample was inadequate to detect differences in the rates. Significant differences in side
effects observed within one hour of misoprostol or
oxytocin administration included higher rates of
observed shivering and fever with misoprostol as
compared to oxytocin (see Table 21).
Two study centers in Nigeria and Thailand collected data on side effects for 24 hours.25 The frequency of shivering decreased significantly
between two and six hours (from 18% at one hour
to 3% in the 2–6-hour period) and fell to almost
zero 7–12 hours later. Fever exhibited a different
trend, however; its frequency increased in the 2–6hour period (from 6% at one hour to 11% in the
2–6-hour period). Reports of diarrhea showed a
similar trend, with the frequency rising to 5% at
2–6 hours and falling to near zero by 13–18 hours.

Side effects observed within one hour of misoprostol or oxytocin administration in the WHO trial

Side effect

Any shivering (%)
Severe shivering (%)
Body temperature >38°C (%)
Body temperature >40°C (%)
Nausea (%)
Vomiting (%)
Diarrhea (%)

Misoprostol (600 µg)

Oxytocin (10 I.U.)

18
1
6
0.1
0.8
0.7
0.4

5
0.2
0.8
0
0.4
0.3
0.1
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In summary, use of 600 µg oral misoprostol in
the third stage of labor, as compared to 10 I.U.
oxytocin administered intramuscularly or intravenously, is associated with an increased frequency of blood loss of 1,000 mL or more and use of
additional uterotonics. Compared to oxytocin, the
frequency of observed side effects with misoprostol is higher, but side effects subside 2–6 hours
after treatment. Therefore, in hospitals and other
tertiary-care settings where active management of
the third stage of labor is the norm and oxytocin
is available, the results of the trial do not support
the use of misoprostol in its stead.

A Randomized, Controlled Trial of
Misoprostol and Oral Ergometrine
in the Management of the Third
Stage of Labor in a Home-Delivery
Setting in Rural Gambia
Gijs Walraven, Medical Research Council, Farafenni, Gambia
Home birth is preferred by and is often the only
option for many women in the developing world.
In fact, 60% of births in the developing world occur
outside a tertiary health care facility. Presence of a
skilled birth attendant at delivery and access to
emergency obstetric care are among the most crucial interventions to decrease maternal morbidity
and mortality. In settings where the current provision of skilled obstetric care remains limited there
is a particular need to consider the role of community-based, traditional birth attendants (TBAs) in
improving safe motherhood.
Results from the WHO trial described above
may be applicable to deliveries in tertiary-care settings, but they are not applicable to the homedelivery setting where the use of injectable medications is not feasible. There is need, therefore, to
identify a method such as oral misoprostol that
can be used for prevention and treatment of PPH
in a rural or community-based setting. To date
there have been no trials of misoprostol for PPH
prevention or treatment in these settings.
Gambia, a primarily rural country in western
Africa, provides a unique opportunity to explore the
potential for TBAs to help reduce maternal morbidity and mortality. In the early 1980s, TBA training
programs were developed and implemented. In
addition to an initial six-week training course, community health nurse midwives provide trained TBAs
with continuing education and supervision.

In a recent study of TBA knowledge of PPH in
the Farafenni region of Gambia, 20 out of 22 TBAs
demonstrated a high level of knowledge about
current PPH treatment standards (i.e., they were
able to describe the steps for active management
of the third stage of labor). Interestingly, although
all TBAs thought that ergometrine (the current
standard treatment in the region) could help prevent excessive blood loss, five TBAs suggested
that more potent drugs are needed. The TBAs also
were eager to improve their knowledge and to participate in further training.
Given the results of this study, implementation
of a large-scale, community-based study of PPH
prevention using TBAs in Farafenni seemed feasible. The Population Council and the Medical
Research Council of the United Kingdom began a
collaboration in 2001 to examine the potential of
misoprostol to prevent PPH at the community
level. This randomized, double-blind, placebo-controlled trial is designed to compare the safety and
efficacy of 600 µg oral misoprostol and 2 mg oral
ergometrine in the prevention of PPH.
The primary endpoint of this study is blood
loss of more than 500 mL. Secondary endpoints
include blood loss of more than 1,000 mL, mean
blood loss, and mean change in pre- and postpartum hemoglobin levels. The sample size (N=1,200)
is sufficient to detect (with 80% power) a 35%
reduction in blood loss of 500 mL or more after use
of misoprostol compared to ergometrine, assuming a 15% incidence of such blood loss in women
treated with ergometrine and allowing for missing
data and multivariate analysis. Recruitment for the
study began in August 2001. To date over 600
women have been enrolled. It is anticipated that
recruitment will end in 2004.

The Pharmacokinetics of Rectal
Misoprostol When Used to Prevent
Postpartum Hemorrhage
Anthony Bamigboye, University of the Witwatersrand,
Nelspruit, South Africa
In a randomized trial comparing the use of 400 µg
rectal misoprostol and 10 I.U. intramuscular syntometrine in the third stage of labor, the rates of
hemorrhage greater than 500 mL and mean blood
loss were similar between the two groups.5 ElRefaey and colleagues found that compared with
placebo, 400 µg oral misoprostol was associated
with a statistically lower rate of hemorrhage.12
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The results of two other studies, O’Brien and colleagues18 and Diab and colleagues,26 support the
possibility that the rectal route of misoprostol
administration may be preferable as it is associated
with less shivering and fever than the oral route.
There is a dearth of studies, however, on the
pharmacokinetics of misoprostol in pregnant
women. Zieman and colleagues27 studied misoprostol’s pharmacokinetics after oral and vaginal
administration in 20 pregnant women. Serum levels of the principal metabolite after administration
of 400 µg were measured at various intervals.
Results indicated that the extent of absorption was
statistically different among the oral and vaginal
groups, suggesting a possible explanation for the
observed difference in clinical efficacy. As this
study did not examine alternative routes of administration (i.e., rectal), further studies are needed.
There are three approaches to investigating
the pharmacokinetics of a molecule such as misoprostol: (1) gas chromatography/mass spectrometry, (2) radioimmunoassay, or (3) enzyme-linked
immunosorbent assay (ELISA). Original pharmacokinetic data on misoprostol measured by gas chromatography are available from its development as
a gastric treatment for peptic ulcers, but the
expensive, laborious nature of this technique
makes it impractical for use by independent
researchers. The presence of an ELISA for misoprostol free acid (the breakdown product of misoprostol) is a more cost-effective alternative.

Summary
Active management of the third stage of labor has
become a standard means for preventing PPH.
Nonetheless, PPH remains a leading cause of
maternal mortality worldwide, disproportionately
affecting women in low-resource settings. For this
reason, development of a prophylactic uterotonic
agent that is easily administered, affordable, and
heat stable is essential. Furthermore, as no preventive measure is completely effective, a treatment for uncontrolled hemorrhage that is easy to
use and cost-effective may have important benefits. Misoprostol has emerged as a promising
alternative for both indications and, given the current body of literature, a case can be made for its
use in settings where standard oxytocics are not
available or where their use is not feasible.
The results of the WHO trial, however, indicate
that in hospitals and other tertiary-care settings
where active management of the third stage of labor

is the norm and oxytocin is available, the use of
misoprostol is not warranted. Nonetheless, there is
much to be learned from the enormous amount of
data carefully collected during this trial. Most important, the results suggest that oxytocin may offer only
a small clinical advantage over misoprostol, as there
was only a 1% difference in the frequency of blood
loss of more than 1,000 mL between the two study
groups. If oxytocin prophylaxis prevents an important number of hemorrhages, then misoprostol prophylaxis must also be deemed beneficial.
Depending on the circumstance, misoprostol
and standard oxytocics may have equal value in
preventing hemorrhage. As the majority of the
world’s women deliver at home or outside a hospital setting, without skilled attendants and without
access to standard oxytocic therapies, misoprostol
could reduce the global burden of PPH. This possibility underscores the need for additional trials
evaluating misoprostol’s use for both prevention
and treatment of hemorrhage.
The experience of and results from the WHO
trial underscore the need to move forward with new
research on the use of misoprostol in the third stage
of labor. Most important, appropriate endpoints
should be chosen and researchers should consider
how best these endpoints could be measured. While
it may be more feasible methodologically to choose
a proxy measure for mortality (e.g., blood loss of
more than 1,000 mL), there is no consensus that this
particular measure is the best one. There is no evidence that this level of blood loss is correlated most
closely with morbidity or mortality and therefore
should be the gold standard. One might argue that
preventing blood loss of 2,000 mL or more or the
need for blood transfusions is more important. In
fact, in the WHO trial transfusion rates were higher
in the oxytocin group, although this difference was
not statistically significant. It may be necessary to
design studies with adequate power to detect differences in rare but potentially more informative endpoints, such as need for blood transfusion or death.
It also may be useful to design future studies that
explore the interaction between treatment with
misoprostol and the use of additional oxytocics.
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Cervical Priming
for Obstetric and
Gynecological Procedures
Many common gynecological procedures require
entry into the uterus through the cervix. These
include surgical abortion, hysteroscopy, endometrial
biopsy, and insertion of an intrauterine device (IUD).
Complications, including pain, cervical lacerations,
or uterine perforations, encountered during these
procedures are usually related to difficulties in passing instruments through the cervical os. These complications occur most commonly in nulliparous or
postmenopausal women or during procedures, such
as hysteroscopy, that require relatively wide cervical
dilation. For procedures such as hysteroscopy and
endometrial biopsy, difficulty in instrumentation has
been a major cause of procedure failure.1
Although mechanical methods have been preferred for cervical dilation, pharmacologic agents
have been developed more recently to “prime”
(dilate or soften) the cervix (see Box 9). Stimulated
by these agents, cervical tissue becomes more
elastic and less resistant. These same changes also
cause the cervical os to dilate and may facilitate
passage of instruments through the cervix, thereby reducing the frequency of complications.
Because paracervical blocks are often necessary to
reduce the discomfort of mechanical dilation, use
of pharmacologic agents to dilate the cervix also
may reduce the need for anesthetics. Moreover,
such agents may reduce the time needed to perform a procedure and increase the ease with which
the procedure is carried out. The major advantages
of misoprostol over other pharmacologic agents
are cost and convenience. Misoprostol also can be
self-administered (either orally or vaginally) at
home prior to arrival at the clinic or hospital.
The cervical-priming effect of misoprostol has
been observed in pregnant and nonpregnant
women of reproductive age, but not yet in postmenopausal women whose hormone levels differ
from those of women of reproductive age. Basic
cellular research is beginning to elucidate specific
pathways of cervical remodeling by misoprostol. It
is believed that this process is mediated by hormonally regulated cytokinases (proteins found
inside and outside of cells that break down other
proteins). Misoprostol is thought to bind with
extracellular steroids (estrogen and gonadotropinreleasing hormone primarily) and extracellular

BOX 9

Methods of cervical priming

Physiological agents
By stimulating physiological changes in the cells of the cervix, these
agents make the cervix more elastic and widen its opening.
• Relaxin
• Prostaglandins (E1, E2, F2-alpha)
Mechanical methods
By exerting a mechanical force on the cervix, these methods widen
the opening of the cervix.
• Hygroscopic dilators (Hanks, Hegar, Kleegman, Pratt)
• Osmotic dilators (laminaria tents [made from an aquatic plant])

membrane steroid receptors to facilitate release of
estrogen and progesterone into cervical cells. In
turn, these steroids bind to their respective intracellular receptors, stimulating DNA transcription of
key proteins. These proteins have been shown to
modify the collagen matrix of the cervix, leading
to greater tissue elasticity. Misoprostol also may
exert its cervical-ripening effect through a similar
but nonsteroid-dependent pathway.

Cervical Priming Prior to
Surgical Abortion
Gillian Penney, University of Aberdeen, Aberdeen, UK
Multiple trials have demonstrated that pharmacologic methods of cervical priming are comparable
to mechanical methods, including laminaria tents.
Prostaglandins tested for this purpose include E1,
E2, and F2-alpha analogs (see Table 22).2–6 Use of
mifepristone for cervical priming prior to surgical
abortion has also been investigated and, in fact,
the drug is registered for this indication in
Europe.
Results of several published studies indicate
that prostaglandins, administered either orally or
vaginally, render surgical terminations in the first
trimester both easier for providers to perform and
more acceptable to patients (see Table 23).7–10
Comparison of misoprostol to both gemeprost and
mifepristone suggests that misoprostol is at least
as effective as measured by cervical dilation (see
Table 24).11–15 Data from Aberdeen, Hong Kong, and
Singapore show that the optimal current priming
regimen for misoprostol is 400 µg orally administered three hours before the procedure.
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TABLE 22 Benefits of cervical priming prior to surgical abortion: Results of cohort and randomized clinical studies
N

Outcome

Conclusion

Overall risk of cervical
injury = 1.03%
Overall risk of uterine
perforation = 0.09%
Overall risk of immediate
complications = 0.7%

Cervical priming (laminaria vs. none)
= relative risk of 0.19
Cervical priming (laminaria vs. none)
= relative risk of 0.17
Cervical priming (laminaria vs. none)
= odds ratio of 0.3

Large cohort studies

Schulz et al. (1983)2

15,438
(≤ 12 wks)
67,175
(13–24 wks)
83,469
(≤ 20 wks)

Kafrissen et al. (1984)3
Ferris et al. (1996)4
Randomized, controlled trials

WHO (1981)5

1,001
(8–12 wks)

Cervical priming with prostaglandin results in significantly easier dilation,
lower blood loss, reduced need for re-evacuation, and reduced infection

de Jonge et al. (2000)6

278
(≤ 12 wks)

Cervical priming with misoprostol results in significantly easier dilation,
shorter procedure, and reduced incidence of treatment failure

TABLE 23 Mechanical vs. pharmacological agents used for cervical priming prior to surgical abortion
N

Mechanical
primer

Pharmacological
primer

627

Laminaria

4 prostaglandin
regimens

• Prostaglandin analogs comparable to laminaria
• No skill needed to administer prostaglandin analogs

Helm et al. (1988)8

78

Lamicel®

Gemeprost

• Gemeprost results in easier dilation and a faster,
less uncomfortable procedure compared to Lamicel®

Gupta and Johnson (1992)9

64

Lamicel®

Prostaglandin

Study

Krishna et al. (1986)

7

Mifepristone
Placebo
MacIsaac et al. (1999)10

106

Laminaria

Oral and vaginal
misoprostol

Results

• Lamicel®, prostaglandins, and mifepristone
equally effective
• Oral mifepristone results in easiest
dilation with fewest side effects
• Vaginal misoprostol more effective than oral
• Misoprostol, oral or vaginal, results in equal
dilation and less pain compared to laminaria

TABLE 24 Misoprostol compared to other pharmacological agents for cervical priming prior to surgical abortion
N

Misoprostol
regimen

Comparison
regimen

90

Vaginal

Gemeprost
Placebo

• Equal efficacy

Ngai et al. (1995)12

64

Oral

Gemeprost

• Misoprostol is cheaper, more effective, and
more convenient

Ngai et al. (1996)13

100

Oral

Mifepristone

• Equal efficacy
• Misoprostol is cheaper and more convenient

Henry and Haukkamaa (1999)14

199

Vaginal

Gemeprost

90

Vaginal

Mifepristone

Study

el-Refaey et al. (1994)

Ashok et al. (2000)15

11

Conclusion

• Equal efficacy
• Misoprostol has fewer side effects than gemeprost
• Mifepristone is more effective, but costs
more and is less available
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TABLE 25 Comparison of misoprostol regimens for cervical priming prior to surgical abortion
Lawrie et al. (1996)

N
Regimen
1 Route
Dose
2 Route
Dose
3 Route
Dose
4 Route
Dose
Conclusion

16

Ngai et al. (1999)

17

Singh et al. (1999a)

18

Singh et al. (1999b)

19

60

225

120

180

Oral
400 µg
Vaginal
800 µg
—
—
—
—
Doses demonstrate efficacy, yet
oral action unpredictable

Oral
200 µg
Oral
400 µg
Vaginal
200 µg
Vaginal
400 µg
400 µg oral dose 3 hours
prior to surgery recommended

Vaginal
200 µg
Vaginal
400 µg
Vaginal
600 µg
Vaginal
800 µg
400 µg vaginal dose
recommended

Vaginal (3 hrs prior)
400 µg
Vaginal (2 hrs prior)
600 µg
Vaginal (2 hrs prior)
800 µg
—
—
400 µg dose 3 hours prior
to surgery more effective
than larger dose administered
closer to procedure

Administration of misoprostol more than 12
hours before surgical abortion can result in incomplete abortion or heavy vaginal bleeding while the
patient is still at home, which could significantly
affect acceptability. Misoprostol administration less
than three hours preprocedure, even with doses
higher than 400 µg administered orally or vaginally, has been shown to result in less of a priming
effect, as measured by cervical dilation and ease of
insertion of instruments (see Table 25).16–19

Cervical Priming Prior to
Hysteroscopy and Other
Gynecological Procedures
Suk Wai Ngai, University of Hong Kong, Hong Kong, China
Use of misoprostol for cervical priming prior to labor
induction and surgical abortion is described extensively in the literature. In contrast, very few studies
have been published on its use prior to gynecolog-

ical procedures such as IUD insertion and hysteroscopy, yet the majority of published studies support its efficacy.20–24 Cervical priming with misoprostol has the potential to reduce the incidence of cervical tearing and uterine perforation during gynecological procedures. Researchers at Queen Mary
Hospital in Hong Kong, China, have undertaken
several studies to examine the cervical priming
effect of misoprostol in nonpregnant women.
In the first study, women admitted for hysteroscopy (generally women of reproductive age
with fertility problems) were randomized to receive
either 400 µg oral misoprostol or a placebo 12
hours prior to the procedure.22 This dose of misoprostol was chosen based on its successful use for
cervical softening prior to first-trimester surgical
evacuation in previous trials conducted at Queen
Mary Hospital. Results indicated that cervixes of
women treated with misoprostol required significantly less force for dilation than those of women
in the placebo group (see Table 26).

TABLE 26 Use of misoprostol for cervical priming prior to hysteroscopy22
Misoprostol (n=21)

Age in years (mean ±S.D.)
Fertility problems (n)
Failed endometrial aspiration (n)
Recurrent vaginal bleeding (n)
Baseline cervical dilation (mean mm ±S.D.)
Cumulative force required for dilation to 8 mm (mean N ±S.D.)

34.5 ±8.0
19
1
1
6.0 ±1.3
40.1 ±20.6

Placebo (n=23)

P-value (95% C.I.)

32.5 ±5.0
21
1
1
3.2 ±1.3
103.7 ±41.7

—
—
—
—
0.001 (1.98–3.7)
0.001 (43.3–83.3)
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The use of misoprostol in postmenopausal
women was also explored. Because the cervixes of
postmenopausal women are typically small and
stenotic, a method of softening the cervix in this
population might help reduce the pain and complications associated with procedures such as hysteroscopy. To test the usefulness of misoprostol for
this indication, 34 postmenopausal women were
randomized to receive either 400 µg oral misoprostol or placebo three hours prior to hysteroscopy.23
The mean ages of two groups differed statistically
(56 years in the misoprostol group vs. 67 years in
the placebo group); weight, height, and body mass
ratio, however, were similar. There were no statistical differences observed in mean cervical dilation
immediately preprocedure, cumulative force necessary to dilate the cervix, or blood loss between
the two groups (see Table 27). Reported side effects
following misoprostol administration were minimal and included slight fatigue and vaginal bleeding. From these results, it does not appear that
misoprostol is useful as a cervical priming agent in
postmenopausal women. The sample size was
small, however.

Summary
Preprocedure administration of misoprostol
appears to be a worthwhile adjunct to gynecological and obstetric procedures that require dilation

TABLE 27 Use of misoprostol for cervical priming prior

to hysteroscopy in postmenopausal women23
Misoprostol
(n=18)

Placebo
(n=16)

4.2 ±1.7
5.0
0–6

4.4 ±1.6
5.0
0–6

Baseline cervical dilation (mm)

Mean ±S.D.
Median
Range
Cumulative force (N)

Mean ±S.D.
Median
Range

27.7 ±23.3 21.8 ±11.8
24.0
19.0
2–101
8–50

Duration of operation (min)

Mean ±S.D.
Median
Range

11.7 ±10.8
7.0
4–41

6.4 ±4.2
5.0
2–15

21.7 ±50.0
5.0
0–20

6.9 ±12.3
3.0
0–50

Blood loss (ml)

Mean ±S.D.
Median
Range

of the cervix and entry into the uterus, perhaps
with the exception of procedures among postmenopausal women. Several published studies
have demonstrated that pretreatment with misoprostol can reduce short-term complications associated with these procedures, including cervical
lacerations and uterine perforations. Moreover,
use of misoprostol may reduce subsequent morbidity caused by cervical stenosis.
Studies suggest that misoprostol is at least as
effective as commonly used methods of mechanical and pharmacologic dilation and has the added
benefit of being inexpensive, convenient, and
acceptable to patients. Although studies differ in
their findings, the optimal priming regimen based
on current data appears to be 400 µg administered
orally three hours prior to a procedure. In women
who are nulliparous, have had previous traumatic
injuries to the cervix, or are postmenopausal,
misoprostol may be less effective, as their cervixes
are likely to be more resistant to dilation. Further
studies in these populations are warranted
because current information is limited, with few
published studies and small sample sizes.
Additional research could help answer other
important questions. Most studies have focused
on the use of misoprostol for cervical ripening
prior to first-trimester terminations with the
patient usually self-administering misoprostol
before coming to the clinic. This type of preprocedure treatment, if safe, could benefit women seeking second-trimester terminations, as dilation of
the cervix during this period takes longer and can
be more painful. The efficacy, safety, and acceptability of this procedure, however, are not wellresearched and have yet to be established.
The extent of dilation caused by misoprostol
is less predictable than that with mechanical dilation and therefore overdilation may be more frequent. Overdilation prior to the insertion of an IUD
may result in higher expulsion rates, or, for hysteroscopic procedures, an inadequate seal around
the hysteroscope. Larger studies testing a broader
range of doses and dosing intervals of misoprostol
for this indication may help to fine-tune its use.
For women who present at clinics for same-day
procedures, waiting three hours for cervical dilation
may not be practical or acceptable. Further research
is needed to investigate whether a particular dose
and route of administration would be effective over
a shorter time interval with tolerable side effects.
Finally, basic laboratory research exploring the
actions of prostaglandins on collagenase and
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other collagenolytic proteases thought to be
involved in cervical remodeling may be useful.
Descriptions of the interaction of gonadosteriods
and estrogen with misoprostol could also be
informative. This type of research, however, is
quite costly and may not be of highest priority.

References
1

Scottish Hysteroscopy Audit Group. 1996. “A Scottish
audit of hysteroscopic surgery for menorrhagia:
Compliance and follow-up,” British Journal of Obstetrics
and Gynaecology 102(3): 249–254.

11 el-Refaey, H., L. Calder, D.N. Wheatley, and A. Templeton.
1994. “Cervical priming with prostaglandin E1 analogues,
misoprostol and gemeprost,” Lancet 343(8907): 1207–1209.
12 Ngai, S.W., K.C. Yeung, T. Lao, and P.C. Ho. 1995. “Oral
misoprostol versus vaginal gemeprost for cervical dilatation prior to vacuum aspiration in women in the sixth to
twelfth week of gestation,” Contraception 51(6): 347–350.
13 ———. 1996. “Oral misoprostol versus mifepristone for
cervical dilatation before vacuum aspiration in first
trimester nulliparous pregnancy: A double blind prospective randomised study,” British Journal of Obstetrics and
Gynaecology 103(11): 1120–1123.
14 Henry, A.M. and M. Haukkamaa. 1999. “Comparison of
vaginal misoprostol and gemeprost as pre-treatment in
first trimester pregnancy interruption,” British Journal of
Obstetrics and Gynaecology 106(6): 540–543.

2

Schulz, K.F., D.A. Grimes, and W. Cates, Jr. 1983. “Measures to prevent cervical injury during suction curettage
abortion,” Lancet 1(8335): 1182–1185.

3

Kafrissen, M.E., K.F. Schulz, D.A. Grimes, and W. Cates, Jr.
1984. “Midtrimester abortion: Intra-amniotic instillation of
hyperosmolar urea and prostaglandin F2 alpha v. dilatation
and evacuation,” Journal of the American Medical
Association 251(7): 916–919.

4

Ferris, L.E., M. McMain-Klein, N. Colodny, N.F. Fellows,
and J. Lamont. 1996. “Factors associated with immediate
abortion complications,” Canadian Medical Association
Journal 154(11): 1677–1685.

5

World Health Organization. 1981. “Vaginal administration
of 15-methyl-PGF2 alpha methyl ester for preoperative
cervical dilatation,” Contraception 23(3): 251–259.

17 Ngai, S.W., Y.M. Chan, O.S. Tang, and P.C. Ho. 1999. “The
use of misoprostol for pre-operative cervical dilatation
prior to vacuum aspiration: A randomized trial,” Human
Reproduction 14(8): 2139–2142.

6

de Jonge, E.T., R. Jewkes, J. Levin, and H. Rees. 2000.
“Randomised controlled trial of the efficacy of misoprostol
used as a cervical ripening agent prior to termination of
pregnancy in the first trimester,” South African Medical
Journal 90(3): 256–262.

18 Singh, K., Y.F. Fong, R.N. Prasad, and F. Dong. 1999a.
“Evacuation interval after vaginal misoprostol for preabortion cervical priming: A randomized trial,” Obstetrics and
Gynecology 94(3): 431–434.

7

Krishna, U., A.N. Gupta, H.K. Ma, I. Manuilova, V. Hingorani,
R.N. Prasad, M. Bygdeman, J. Herczeg, D. Obersnel-Kveder,
A. Losa et al. 1986. “Randomized comparison of different
prostaglandin analogues and laminaria tent for preoperative cervical dilatation. World Health Organization Special
Programme of Research, Development and Research
Training in Human Reproduction: Task Force on Prostaglandins for Fertility Regulation,” Contraception 34(3): 237–251.

8

9

Helm, C.W., N. Davies, and R.J. Beard. 1988. “A comparison of gemeprost (Cervagem) pessaries and Lamicel tents
for cervical preparation for abortion by dilatation and suction,” British Journal of Obstetrics and Gynaecology 95(9):
911–915.
Gupta, J.K. and N. Johnson. 1992. “Should we use
prostaglandins, tents or progesterone antagonists for
cervical ripening before first trimester abortion?”
Contraception 46(5): 489–497.

10 MacIsaac, L., D. Grossman, E. Balistreri, and P. Darney.
1999. “A randomized controlled trial of laminaria, oral
misoprostol, and vaginal misoprostol before abortion,”
Obstetrics and Gynecology 93(5 Pt 1): 766–770.

15 Ashok, P.W., G.M. Flett, and A. Templeton. 2000. “Mifepristone versus vaginally administered misoprostol for cervical priming before first-trimester termination of pregnancy: A randomized, controlled study,” American Journal of
Obstetrics and Gynecology 183(4): 998–1002.
16 Lawrie, A., G. Penney, and A. Templeton. 1996. “A randomised comparison of oral and vaginal misoprostol for cervical
priming before suction termination of pregnancy,” British
Journal of Obstetrics and Gynaecology 103(11): 1117–1119.

19 ———. 1999b. “Vaginal misoprostol for pre-abortion cervical priming: Is there an optimal evacuation time interval?” British Journal of Obstetrics and Gynaecology
106(3): 266–269.
20 Fung, T.M., M.H. Lam, S.F. Wong, and L.C. Ho. 2002. “A randomised placebo-controlled trial of vaginal misoprostol for
cervical priming before hysteroscopy in postmenopausal
women,” British Journal of Obstetrics and Gynaecology
109(5): 561–565.
21 Ngai, S.W., Y.M. Chan, and P.C. Ho. 2001. “The use of misoprostol prior to hysteroscopy in postmenopausal women,”
Human Reproduction 16(7): 1486–1488.
22 Ngai, S.W., Y.M. Chan, K.L. Liu, and P.C. Ho. 1997. “Oral
misoprostol for cervical priming in non-pregnant women,”
Human Reproduction 12(11): 2373–2375.
23 Preutthipan, S. and Y. Herabutya. 1999. “A randomized controlled trial of vaginal misoprostol for cervical priming before
hysteroscopy,” Obstetrics and Gynecology 94(3): 427–430.
24 ———. 2000. “Vaginal misoprostol for cervical priming
before operative hysteroscopy: A randomized controlled
trial,” Obstetrics and Gynecology 96(6): 890–894.

Report of a seminar

33

34

CURRENT

MEDICAL

In most developing countries, access to new drug
therapies is limited, especially where drugs are
expensive or require sophisticated technologies or
skills. Little research and funding have been devoted to finding effective and inexpensive technologies that are appropriate to low-resource settings.
Consequently, providers often modify standard
regimens to suit their own needs or develop their
own treatments based on available drugs. One
example of this is the off-label use of misoprostol
for a host of reproductive health indications.
Misoprostol is especially well-suited for use in
developing countries and has several important
advantages over other available treatment options.
Despite these advantages, there are no standard
or labeled regimens for any of these indications.
Instead, providers have relied on the medical literature and colleagues in the field, as well as their
own experience, for information on effective regimens. Consequently, both in the medical literature
and in clinical practice there is considerable variation in the regimens used.

The Use of Misoprostol to
Improve Gynecological and
Obstetric Health in Brazil,
Jamaica, and the United States1
Shelley Clark, Population Council, New York, NY, USA
Misoprostol is frequently solely perceived as an
abortifacient drug. Yet mounting evidence demonstrates that it can be used to treat an array of
reproductive health conditions that fall into three
main categories: (1) abortion, (2) uterine evacuation, and (3) labor and delivery.

Methods
To document the off-label use of misoprostol and
to capture some of the variation in regimens used
in clinical practice, researchers conducted a survey
of obstetricians and gynecologists in Brazil,
Jamaica, and the United States. From February
1999 to May 2000, 228 obstetricians and gynecologists were interviewed in Brazil (n=123), Jamaica
(n=53), and the United States (n=52). Using tele-

PRACTICE

phone interviews, researchers asked providers
about their knowledge and use of misoprostol for
ten distinct reproductive health indications. If a
provider reported using misoprostol for a particular reproductive health indication, he or she was
asked to describe the regimen used, including
dosage amount, number of doses, timing of
doses, and route of administration. Providers were
also asked to describe commonly observed side
effects. They were then asked to estimate the efficacy of misoprostol for the chosen indication and
patient acceptability of the drug.
In all three countries, the “snowball” method
was used to identify potential respondents. Researchers asked a core of knowledgeable providers
to refer other providers who might be willing to
participate in the survey. It is important to note that
given this method of data collection, this study
does not provide an overall estimate of the prevalence of misoprostol use. Rather it shows a range of
its use and variation in the regimens prescribed
among a nonrepresentative sample of providers.

Uses of misoprostol
In all three countries, there was a network of
providers who had considerable experience using
misoprostol. In Brazil and Jamaica there was
intense interest in and enthusiasm about misoprostol. In comparison, use of the drug was less
common and support for its use more tepid in the
United States.
The use of misoprostol for abortion induction
was well known among the providers interviewed
in all three countries. Between 26% and 39% used
misoprostol alone for first-trimester abortion. Use
of misoprostol for second-trimester abortion, either
in combination with dilation and evacuation (D&E)
or to induce labor, was less common. However, the
use of misoprostol to prime the cervix prior to surgical abortion was widely practiced in Jamaica (52%).
Misoprostol appears to be most frequently
used for evacuating the uterus following a pregnancy failure. A large percentage of providers in
Brazil and Jamaica (73%) reported using misoprostol for treatment of intrauterine fetal death.
Similarly large percentages of providers in these
two countries reported using misoprostol to treat
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missed abortion. Reports of use for incomplete
spontaneous abortions were rare.
Use of misoprostol during labor and delivery
was especially common in Jamaica. A large majority of providers from Jamaica (87%) reported using
misoprostol to induce labor. In contrast, providers
in all three countries seldom used misoprostol for
prevention or treatment of postpartum hemorrhage (see Table 28).
Misoprostol to induce abortion. Results of the
survey demonstrate that providers were exploring
a variety of regimens for a range of abortion indications, including first- and second-trimester
induction of abortion and cervical priming prior to
surgical abortion. For each indication, researchers
expressed a strong preference for vaginal administration of the drug. Several providers, particularly
in Brazil, however, used a combination of oral and
vaginal administration. Providers reported using
anywhere from 50- to 900-µg doses and an average of three to four doses of misoprostol for firsttrimester induction. In contrast, regimens for cervical priming prior to surgical abortion used about
half that dosage.
Overall, providers did not report a large number of side effects with the use of misoprostol for
abortion induction. By far the most common side
effect reported was gastrointestinal discomfort. A
small number of providers also mentioned bleeding, vomiting, nausea, cramps, and pain. In addition, while providers offered a wide range of treat-

TABLE 28 Providers reporting using misoprostol for

women’s health indications in Brazil, Jamaica, and the
United States (N=228)
Indication

%

Induced abortion

First-trimester induction
Second-trimester D&E
Second-trimester labor induction
Cervical priming prior to surgical abortion

27
23
13
21

Uterine evacuation

Intrauterine fetal death
Missed abortion
Incomplete abortion

61
57
16

Labor and delivery

Cervical softening
Labor induction
Prevention or treatment of postpartum hemorrhage

14
46
8

ment regimens, they were remarkably consistent
in their reports of the drug’s efficacy and patient
acceptability. Providers typically rated efficacy
above 90% and gauged the acceptability to their
patients to be between 80% and 90%.
Although some regimens were reported to be
used commonly in practice, many of them have
yet to be tested in the research setting and therefore do not represent recommended treatment
regimens. Table 29 compares the most common
regimens found in clinical practice in the three
countries to those recommended in a recent
review article by Goldberg and colleagues.2
Although the use of misoprostol for firsttrimester abortion induction is common in all
three countries, it was not recommended in the
review by Goldberg and colleagues. The review
did recommend two regimens for secondtrimester abortion, roughly comparable to the
regimens found in clinical practice. The recommendation for cervical priming prior to abortion,
however, contrasts sharply with the regimen
used in practice, which consists of a much lower
dose administered further in advance of the procedure (see Table 29).
In countries like Brazil, where abortion is legally restricted, there are frequent reports documenting women’s covert use of the drug. In general,
misoprostol is a much safer way to self-induce
abortion than other methods women use in these
circumstances. Nonetheless, women who use the
drug covertly and experience complications may
not have access to medical advice or be able to
seek prompt care in case of an emergency.
Misoprostol for uterine evacuation after pregnancy failure. More than 60% of providers who
reported using misoprostol for uterine evacuation
after pregnancy failure administered the drug vaginally, and nearly a third reported using a regimen
combining both vaginal and oral administration. A
wide range of regimens was described for each
indication, with reported doses ranging from 25 µg
to 800 µg and the average number of doses from
three to six.
Overall, providers did not report many side
effects with the use of misoprostol for treatment of
pregnancy failure. However, one provider reported
two cases of uterine rupture in women who were
six months pregnant and had experienced IUFD.
These women were given 1,200 µg, a dose far
greater than the recommended dosage of 100–200
µg, but consistent with doses cited by other
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TABLE 29 Comparison of most commonly reported regimens and best-practice regimens for use of misoprostol for women’s

health indications
Indication

Most commonly reported regimen

Medical literature review

First-trimester induction

• 400 µg vaginal; 2 doses; q 6, 12, or 24 hrs
• 200 µg vaginal; 1–4 doses; q 6 or 12 hrs

• Not recommended where safe
alternatives exist

Second-trimester D&E

• 400 µg vaginal; 1 dose
• 200 µg vaginal; 2–4 doses; q 4, 6, 12, or 24 hrs

• Not recommended where safe
alternatives exist

Second-trimester labor induction

• 200 µg vaginal; 2 doses; q 6 or 12 hrs

• 200–600 µg vaginal; q 12 hrs

Cervical priming prior to surgical abortion

• 50–100 µg vaginal; 1–3 doses; q 12 hrs before surgery • 400 µg vaginal; q 3–4 hrs before surgery

Induced abortion

Uterine evacuation

Intrauterine fetal death

• 100 µg vaginal; 2 doses; q 12 or 24 hrs
• 200 µg vaginal; 1–4 doses; q 4, 6, 12, or 24 hrs

• 200 µg vaginal (2nd trimester); q 12 hrs
• 100 µg vaginal (3rd trimester); q 12 hrs
• 50 µg vaginal (at term); q 12 hrs

Missed abortion

• 400 µg vaginal; 1 dose
• 200 µg vaginal; 1–4 doses; q 4, 6, 12, or 24 hrs

• 800 µg vaginal; 1–2 doses; q 24 hrs

Incomplete abortion

• 200 µg vaginal; 2 doses; q 4, 6, or 12 hrs

• Not recommended

Cervical softening

• 50 µg vaginal; 1 dose
• 200 µg vaginal; 1 dose

• 25 µg vaginal; q 4–6 hrs

Labor induction

• 50–100 µg vaginal; 2 doses; q 12 or 24 hrs

• 25 µg vaginal; q 4–6 hrs

Prevention of postpartum
hemorrhage

• 200 µg vaginal; 1 dose
• 400 µg rectal; 1 dose
• 200 µg vaginal; 2 doses

• Not recommended if standard
oxytocics available

Labor and delivery

providers in the survey. Providers indicated that
misoprostol is more than 90% effective and 80%
acceptable to women when used to treat pregnancy failure.
Given the variation in reported regimens, it is
difficult to identify the most common treatments
for uterine evacuation. For early missed abortion,
the review article by Goldberg and colleagues recommends one or two doses of 800 µg vaginal
misoprostol every 24 hours. In practice, the
providers surveyed tended to use about half that
dose for this indication. Finally, Goldberg and colleagues note that little evidence supports the use
of misoprostol for treatment of incomplete spontaneous abortions. Yet a sizable majority of providers
in the study reported using two doses of 200 µg
every 4, 6, or 12 hours for this indication.

Misoprostol for labor and delivery. For labor
induction and cervical softening, a majority of
providers reported that they administer misoprostol vaginally. While most providers surveyed indicated that they use between 25 µg and 50 µg, others reported using doses as high as 600 µg. For
both labor induction and cervical softening, the
amount of misoprostol typically administered is at
least double that recommended in the review article by Goldberg and colleagues. Side effects of
misoprostol when used for these indications
included uterine hyperstimulation, pain, and precipitate labor. Providers consistently judged the
drug’s efficacy and acceptability as over 80%.
Providers who reported using misoprostol for
either prevention or treatment of PPH were divided between those who favored vaginal (53%) or
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rectal (33%) administration. For prevention of PPH,
providers reported administering between 200 µg
and 400 µg, either vaginally or rectally. (The
review article by Goldberg and colleagues does
not recommend misoprostol for prevention of PPH
if other drugs are available.) A few providers mentioned side effects including cramps, gastrointestinal discomfort, and fever or chills when misoprostol was used for this indication.

Conclusions
Given the method of data collection, it is not possible to estimate the prevalence of misoprostol use
by providers in Brazil, Jamaica, or the United
States. Nonetheless, it is clear that there is high
demand for misoprostol among obstetricians and
gynecologists, especially in Brazil and Jamaica.
Providers also reported a high level of perceived
efficacy and acceptability for all indications. Owing
to a lack of practice guidelines and standard regimens, however, there is tremendous variation in
the indications for which misoprostol is used and
in the regimens used for each of these indications.
Off-label use of this drug poses several limitations. Some providers may underestimate its
potency and give their patients excessively large
doses. Many individual providers consistently
reported giving much higher doses for the various
indications than are currently substantiated in the
medical literature. Without proper guidelines detailing when and how misoprostol should be used,
providers may use regimens that are not safe or
effective. In addition, providers may use misoprostol for indications for which is it not necessary or
not the best available treatment. For example, as
with other labor-inducing drugs, providers may use
misoprostol for their convenience and prescribe it
more often than medically necessary to increase
the number of “daytime deliveries.”

Assessment of Misoprostol Use
in Developing Countries
Elizabeth Westley, EngenderHealth, New York, NY, USA
and Jacqueline Sherris, Program for Appropriate
Technology in Health, Seattle, WA, USA
EngenderHealth and the Program for Appropriate
Technology in Health (PATH) conducted an assessment of misoprostol use, focusing on developing
countries and with a particular emphasis on its use

for abortion. The study’s three primary objectives
were to:
• investigate the availability and use of misoprostol;
• explore the potential impact of misoprostol
availability on postabortion complications; and
• identify information needs of key stakeholders,
including women, providers, and pharmacists.
Following a literature review, researchers conducted a survey of providers in 23 countries and a
qualitative assessment of misoprostol use among
women, providers, pharmacists, and pharmaceutical representatives in four countries.

Survey of providers
In collaboration with the field offices of EngenderHealth and PATH, 70 providers from 23 countries
were surveyed by mail, fax, or e-mail. The selfadministered survey included questions about
providers’ knowledge and opinions regarding the
availability and use of misoprostol both within and
outside the medical establishment.
Respondents from countries where the drug is
registered were most likely to report misoprostol
use for women’s health indications. Respondents
from countries where misoprostol is not registered
reported very little use, particularly in Africa.
Among respondents who reported using misoprostol, commonly reported indications for use
were treatment of IUFD and uterine labor induction. Respondents reported high acceptability.
Many reported that self-administration of
misoprostol, in order to induce abortion, was a
common practice in their communities. Over half
of the respondents had treated women with
incomplete abortion who appeared to have
induced abortion with misoprostol. Reports of
women using misoprostol for this purpose were
more widespread among providers from Latin
America. Almost 90% of respondents there who
reported seeing women who had self-administered misoprostol felt it was as safe as or safer
than other available methods to induce abortion.
Some respondents reported anecdotally that
where misoprostol was available, complications
from induced abortion were less severe, resulting
in less-frequent mortality or severe morbidity.

Qualitative assessment of misoprostol use
in four countries
An in-depth qualitative assessment of misoprostol
use and availability was conducted in two countries
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in Latin America, one country in Asia, and one in
Africa. Researchers chose countries where abortion
is highly restricted, somewhat restricted yet rarely
available, or legal but with limited access. Participants included over 100 women of reproductive age
(including 23 women presenting at clinics for treatment of postabortion complications), 83 providers
from the formal sector (including obstetricians and
gynecologists, general practitioners, and nurses),
19 lay practitioners and traditional healers, 37
pharmacists, and four pharmaceutical representatives. The assessment drawn from their comments
offers insight into the use and availability of misoprostol within a variety of legal, social, and economic settings.
In-depth interviews with women. Knowledge
of misoprostol was not widespread among the
93 women interviewed in the four countries,
although younger and better-educated women
were more likely to be aware of the drug. In some
cases, women were not able to distinguish
between misoprostol, mifepristone, emergency
contraceptive pills, and oral contraceptives.
Women indicated that they receive information
about pregnancy termination primarily from their
friends and relatives.
In-depth interviews with women treated for
postabortion complications. Over half of the 23
women interviewed reported using misoprostol.
Reported doses and regimens varied widely, with
doses of as many as eight tablets recommended
to them by pharmacists or health care practitioners, to be administered orally, vaginally, or orally
and vaginally. (Use of the “three-up/three-down”
protocol, in which three tablets are taken orally
and three are taken vaginally, was widespread in
one country.) Some women reported taking the
tablets orally with special teas, and in one case
with an injection. Oral administration was recommended to some women so that a provider would
not be able to find evidence of the drug if the
woman later required treatment.
Many women in the sample expressed fear
and confusion about not knowing what to expect
when taking misoprostol, and some reported
being frightened by the bleeding and pain they
experienced. Women who attempted abortion
commonly stated that the experience was lonely
and frightening, that they usually did not know
what to expect, and that they sought assistance
only after unsuccessful attempts. These responses
are from women who required treatment at a
health care facility, and therefore do not represent

the opinions of those who had successful abortions and did not present for postabortion care.
In-depth interviews with pharmacists. Results
of interviews with women suggest that pharmacists are the front-line providers of misoprostol in
countries where misoprostol is available but abortion is illegal or access to abortion is limited.
However, pharmacists were understandably reluctant to describe their experiences providing misoprostol to women seeking to terminate their pregnancies. While pharmacists commonly acknowledged that misoprostol could be used for abortion,
they rarely reported providing misoprostol for that
indication.
In-depth interviews with pharmaceutical representatives. Three of the four pharmaceutical representatives interviewed acknowledged obstetric
and gynecological uses of misoprostol, and all
stated that the company that markets and distributes misoprostol cannot and thus does not promote off-label use of the drug.
In-depth interviews with providers. All
providers reported using misoprostol for many
women’s health indications, although obstetricians
and gynecologists appeared to use the drug for
the widest range of indications. Providers emphasized the need for standardized practice guidelines
but seemed reluctant for information about misoprostol to be disseminated to women. They voiced
concerns about uterine rupture and other side
effects and complications but acknowledged a significant positive impact of use of the drug on
women’s health, particularly a marked reduction in
the number of women presenting with complications of induced abortion.

Summary
The combination of widespread off-label use of
misoprostol and few conclusive large-scale clinical
trials leaves policymakers, drug regulators, pharmaceutical companies, providers, and women in
an unusual and uncomfortable position. On the
one hand, a large and growing group of providers,
particularly in developing countries, has discovered a range of uses of misoprostol for improving
reproductive health care. On the other hand, pharmaceutical companies have shown no interest in
developing misoprostol for any of these women’s
health indications.
The potential for misoprostol to improve
women’s health makes its continued use in obstetrics and gynecology almost inevitable. Effective
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information dissemination strategies are therefore
essential to ensure safe and effective use of the
drug. Practice guidelines should be simple to
understand and applicable to a wide range of situations. Materials should be developed in local languages. In addition, providers would benefit from
articles published in local medical journals, as they
often have limited access to journals from other
countries. Because the Internet is a frequently
used source of information, accurate, evidencebased information on misoprostol use for
women’s health indications, including for pregnancy termination, should be made available online.
Information dissemination efforts should also target pharmacists who provide misoprostol for preg-

nancy termination even where legal restrictions
prohibit them from doing so. In settings where
abortion is highly restricted, women have few
sources for accurate information, and therefore
creative dissemination strategies are necessary.
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PRIORITIES FOR
AND POLICY

RESEARCH

Meeting participants agreed that a major priority
for research and policy is creation of a solid clinical
science base for all women’s health indications for
which misoprostol is effective. A second priority is
to ensure the availability of misoprostol by registering it for women’s health indications and guaranteeing that its availability is not subject to economic or political factors. Once misoprostol is available
and accessible in a country, providers must be
trained, guidelines created, and women educated
so that use of the drug is safe and effective. Finally,
a broader policy strategy is necessary to generate
support for needed program development.

• Develop a dose-response curve by gestational
age over the entire course of a pregnancy with
respect to uterine contractility and cervical
softening;

Goals

• Determine the feasibility of developing doses
smaller than 100 µg and 200 µg.

• Determine the feasibility of integrating misoprostol use into a variety of health care service
delivery settings;
• Investigate patient and provider acceptability,
perceived and actual benefit of treatment, and
actual use and practice patterns;
• Establish the effect of pre-administration moistening and pH on efficacy and absorption of
misoprostol when administered vaginally; and

Overall
• Create awareness about the potential of misoprostol for women’s health indications;
• Generate scientific understanding of misoprostol for women’s health indications; and
• Improve safe and effective use of misoprostol
for women’s health indications.

Induced abortion
• Identify safe and effective regimens for firstand second-trimester induction with misoprostol; and
• Explore the use of misoprostol for cervical
ripening prior to second- and third-trimester
dilation and evacuation procedures.

It is important that:
• women’s health and policy groups understand
the issues, formulate positions on use of misoprostol, and disseminate these positions;
• medical providers understand the benefits and
limitations of misoprostol’s use for women’s
health indications;
• researchers coordinate research plans, drug
development, and other efforts critical to creating good practice guidelines; and
• members of all of the above groups present
information garnered from research in a standardized way to educate and inform politicians,
lawmakers, and other professionals.

Research Priorities

Uterine evacuation after pregnancy failure
• Compare medical management with surgical
and expectant management for treatment of
incomplete and missed abortion; and
• Compare medical and surgical management of
IUFD.

Labor induction (viable pregnancy)
• Identify the best regimen for labor induction;
• Define the benefits and risks of labor induction
with misoprostol in women with previous
cesarean section; and
• Compare the use of misoprostol for labor induction remote from term with current treatment
alternatives such as oxytocin or dinoprostone.

In general
• Explore the biology as well as the advantages and
disadvantages of various routes of administration:
buccal, sublingual, rectal, oral, and vaginal;

Use in the third stage of labor
• Explore the role of misoprostol in the prevention
of PPH in a range of health care delivery settings;
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• Evaluate the use of misoprostol in the treatment of PPH in a range of health care delivery
settings; and

– supporting development of leaders in the
field who can provide training and expertise
on use of the technology.

• Determine appropriate proxies for measuring
morbidity and mortality in studies of treatment
and prevention of PPH.

• Educate women on the appropriate use of
misoprostol for women’s health indications by:
– assessing informational needs and appropriate vehicles of information dissemination;
and
– employing strategies that allow autonomy in
reproductive health decisionmaking in formal
and informal settings.

Cervical priming
• Evaluate the use of misoprostol for cervical
priming prior to IUD insertion and hysteroscopy; and
• Identify a regimen for using misoprostol for
cervical priming for same-day procedures.

Policy Priorities
Disseminate information
• Increase discussion of use of misoprostol for
women’s health indications in professional
forums by:
– building consensus on guidelines for clinical
practice;
– fostering and encouraging discussion at
national and international meetings; and
– convening informational and technical
seminars.
• Train medical providers by:
– creating practice guidelines tailored to local
context and type of provider; and

• Generate awareness among key advocacy
groups.

Develop a dedicated product
• Register a misoprostol product for new indications in the United States and abroad; and
• Develop alternate formulations:
– 25 and 50 µg tablets; and
– Vaginal, rectal, buccal, and sublingual
formulations, where necessary.

Stimulate awareness in the funding
community
• Pursue major investment for low-resource settings where potential cannot be met without
generous funding; and
• Generate funding to support research, education, dissemination, and policy efforts.
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THE FUTURE OF MISOPROSTOL
FOR WOMEN’S HEALTH
This report outlines the potential of misoprostol
(Cytotec®) for a range of women’s health indications. A growing body of knowledge supports its
use for induced abortion, uterine evacuation after
pregnancy failure, cervical priming, labor induction, and management of the third stage of labor.
Meeting participants noted that despite misoprostol’s medical and scientific promise, there is
an inadequate level of funding support for
research from both private and public entities to
continue the work outlined here. Some of the challenges faced are common to drugs used in
women’s health in general and reproductive health
in particular. Fears about liability and teratogenicity inhibit research on drugs for use in pregnant
women. In addition, controversies surrounding
misoprostol have hampered progress toward
expanding its use. Stories in the mainstream
media have dramatized the rare but tragic fatal
outcomes due to misuse of misoprostol in labor
induction. And because misoprostol is used to
induce abortion, pharmaceutical companies
responsible for its development and marketing are
not supporting expanded use of the drug. For
these reasons, it is imperative that women’s health
researchers, providers, advocates, policy leaders,
and educators assume leadership roles and work
together to develop and fulfill a common agenda
to encourage research and development.
Misoprostol should not be promoted as “a
magic bullet,” nor should its potential be lost due
to lack of support from industry and governments.
Policy discussions must be accompanied by
research conclusions from rigorously conducted
pharmacologic, clinical, and social science studies.
Science, however, must also be realistic about the
real-world situations women face. The potential
public health importance of this drug in lowresource settings (it is inexpensive, easy to store,

and readily available) should be taken into account
when assessing the appropriate role of misoprostol in health service delivery. Similarly, research to
specify optimal clinical protocols for the use of
misoprostol should recognize the importance of
simplicity and clarity. It is likely that such protocols
will have their most important public health roles
in settings that lack sophisticated medical supervision or resources.
Statistical significance should not be the only
measure of clinical significance. It is important to
disseminate information about the evidence-based
uses of this medication. It is also important to continue research on indications that lack adequate
scientific evidence but for which the drug is
already being used in clinical and lay practice.
Presentations at this meeting highlighted the huge
variation in the clinical use of misoprostol. The
counterintuitive dose-related effects of this drug
on the pregnant uterus—a higher dose is needed
to trigger uterine contractions early in pregnancy,
and a much lower dose is needed in later pregnancy—is essential information for both clinicians and
lay people. Similarly the risks of inappropriate use
must be part of the medical dialogue among clinicians and lay audiences. Researchers should continue to explore dosing and routes of administration for a wide range of clinical indications.
Financial investment will be required for misoprostol to meet its potential. Such investment
could result in the registration of a product for several women’s health indications. Funding also is
needed for education and information dissemination among professional and lay audiences.
This meeting began a dialogue among researchers, providers, advocates, policy leaders, and educators. Participants affirmed a commitment to continue the work needed to realize the potential of
misoprostol as a women’s health technology.
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AGENDA

7 May 2001
State-of-the-Art Research
Session 1: Induced Abortion
(Misoprostol Alone)
• Review of first- and second-trimester
induced abortion

Speaker: John Jain, University of Southern California,
Los Angeles, CA, USA
• First-trimester induced abortion:
A life-table analysis

Speaker: Bryna Harwood, University of Southern
California, Los Angeles, CA, USA
• First-trimester induced abortion in India

Session 4: Postpartum Hemorrhage
• The WHO trial

Speaker: A. Metin Gulmezoglu, World Health
Organization, Geneva, Switzerland
• Overview of research experience: Past and
present

Speaker: Justus Hofmeyr, University of the
Witwatersrand, Nelspruit, South Africa
• Prevention of postpartum hemorrhage in the
home delivery setting in rural Gambia

Speaker: Gijs Walraven, Medical Research Council,
Farafenni, Gambia

• Second-trimester induced abortion in Thailand

• The pharmacokinetics of rectal misoprostol
when used to the prevent postpartum
hemorrhage

Speaker: Yongyoth Herabutya, Ramathibodi Hospital,
Bangkok, Thailand

Speaker: Anthony Bamigboye, University of the
Witwatersrand, Nelspruit, South Africa

Speaker: Kurus Coyaji, K.E.M. Hospital, Pune, India

Session 2: Uterine Evacuation After
Pregnancy Failure

Session 5: Cervical Ripening for Obstetric
and Gynecological Procedures

• Incomplete and missed abortion in
early pregnancy

• Cervical ripening prior to surgical abortion

Speaker: Salina M.W. Pang, Chinese University of
Hong Kong, Hong Kong, China
• IUFD in the second and third trimester

Speaker: Hazem el-Refaey, Chelsea and Westminster
Hospital, London, UK
Session 3: Labor Induction
• Review of labor induction with misoprostol:
Route of administration, efficacy, safety, and
potential concerns

Speaker: Allan Templeton, University of Aberdeen,
Aberdeen, UK
• Labor induction with complicated labor: Postcesarean delivery, pre-eclampsia, pre-term/term
premature rupture of membranes

Speaker: Luis Sanchez-Ramos, University of Florida,
Jacksonville, FL, USA

Speaker: Gillian Penney, University of Aberdeen,
Aberdeen, UK
• Cervical ripening prior to hysteroscopy and
other gynecological procedures

Speaker: Suk Wai Ngai, University of Hong Kong,
Hong Kong, China

Current Clinical Practice
• Results of a survey in Jamaica, Brazil, and the
United States

Speaker: Shelley Clark, Population Council, New York,
NY, USA
• Route of administration: Considering efficacy
and acceptability

Speakers: Bryna Harwood, University of Southern
California, Los Angeles, CA, USA; Caitlin Shannon,
Population Council, New York, NY, USA
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8 May 2001
Misoprostol: An Important
Technology for Women’s Health
• Misoprostol in current research and clinical
practice

Speaker: Felicia H. Stewart, Center for Reproductive
Health Research & Policy, University of California, San
Francisco, CA, USA
• Protecting the potential of misoprostol:
Ensuring availability and appropriate use

Speaker: Beverly Winikoff, Population Council, New
York, NY, USA

Gaps and New Directions in Research
• What are the most established/promising
indications?
• How can we improve upon the regimen for
these indications?
• Can we develop safe/effective regimens for the
remaining indications?

The Role of NGOs and Other
Nonprofit Organizations in
Ensuring the Availability and
Supporting the Use of Misoprostol
• Creating awareness of the application and
appropriate use of misoprostol in clinical
practice

Speaker: Kirsten Moore, Reproductive Health
Technologies Project, Washington, DC, USA
• From physicians to lay practitioners:
Educating providers

Speaker: Jodi Magee, Physicians for Reproductive
Choice and Health, New York, NY, USA
• Supporting the availability and use of
misoprostol in developing countries

Speakers: Elizabeth Westley, EngenderHealth, New
York, NY, USA; Jacqueline Sherris, Program for
Appropriate Technology in Health, Seattle, WA, USA

• Can we develop new indications?

Speakers: Alisa Goldberg, University of California, San
Francisco, CA, USA; Kurus Coyaji, K.E.M. Hospital, Pune,
India

The Role of Provider Groups in
Supporting the Appropriate Use
and Development of Misoprostol
• Supporting and providing education and
training for health care providers
• Promoting progressive hospital policies
• Protecting providers from potential legal issues

Speakers: Vicki Saporta, National Abortion Federation,
Washington, DC, USA; Ruth Shaber, Kaiser Permanente
Medical Group, Oakland, CA, USA
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